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A C h Acetylcholine 
4-AP 4-aminopyridine 
Apa Apamin 
A T P Adenosine triphosphate 
BKca Large-conductance calcium-activated potassium channel 
[Ca2+]i Intracellular calcium concentration 
CO2 Carbon dioxide 
C R C Concentration-response curve 
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E D C F Endothelium-derived contracting factor 
E D R F Endothelium-derived relaxing factor . 
E D H F Endothelium-derived hyperpolarizing factor 
Endo Endothelium 
D M S O Dimethyl sulphoxide 
Emax Maximal relaxation 
e N O S Endothelial nitric oxide synthase 
E R Estrogen receptor 
E R E Estrogen response element 
17P-E2 17p-Estradiol 
ET-1 Endothelin-1 
H D L High-density lipoprotein 
H R T Hormone replacement therapy 
IBX Iberiotoxin 
IKca Intermediate-conductance calcium-activated potassium channel 
iNOS Inducible nitric oxide synthase 
IP3 Inositol 1,4,5-trisphosphate 
IP3R Inositol 1,4,5-trisphosphate receptor 
K A T P ATP-sensitive potassium channel 
Kca Calcium-activated potassium channel 
K i r Inward rectifier potassium channel 
K v Voltage-gated potassium channel 
L B D Ligand-binding domain 
L D L Low-density lipoprotein 
L - N A M E N*^-nitro-L-arginine methyl ester 
L - N N A NG-nitro-L-arginine 
、 M A B P Mean arterial blood pressure 
mg/d milli-grams per day 
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mg/dl milli-grams per deciliter 
m m milli-metre 
m M milli-molar 
m N milli-Newton 
N O Nitric oxide 
O D Q 1 H-[ 1,2,4]oxadizolo[4,3-a]quinoxalin-1 -one 
O V X Ovariectomy (or ovariectomized) 
pDj Negative logarithm of the dilator concentration that causes 5 0 % of 
the maximum relaxation 
pECso Negative logarithm of the constrictor concentration that causes 5 0 % 
of the maximal contraction 
Phe Phenylephrine 
PGI2 Prostacyclin 
PI3K Phosphatidylinositol 3-kinase 
P K C Protein kinase C 
P M Plasma membrane 
Raf Raloxifene 
S.D. Sprague-Dawley 
S E R M Selective estrogen receptor modulator 
S H R Spontaneously hypertensive rat 
SKca Small-conductance calcium-activated potassium channel 
S N P Sodium nitroprusside 
Tarn Tamoxifen 
T E A + Tetraethylammonium ions 
IJ46619 9,11-dideoxy-l la9a-epoxymethanoprostaglandin F2a 
V G C C Voltage-gated calcium channel 
V S M C Vascular smooth muscle cell 
W K Y Wistar-Kyoto rat 
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ABSTRACT 
After menopause, w o m e n experience higher risks of cardiovascular diseases. 
Hormone replacement therapy (HRT) was commonly used to relieve the 
postmenopausal symptoms. However, findings from recent H R T clinical trials have 
questioned its long-term safety since H R T users had higher risks for heart attack and 
stroke. In searching for alternative therapies to H R T , selective estrogen receptor 
modulators (SERMs) have been developed. Raloxifene, a 2"'^-generation S E R M with 
anti-estrogenic effects on breast and uterus, is now approved for the treatment of 
postmenopausal osteoporosis. Its effect on the cardiovascular system is currently being 
evaluated. Raloxifene relaxes systemic blood vessels in vitro, but the exact mechanisms 
underlying the vascular action remain unclear, particularly in the pulmonary circulation. 
It is also unknown whether raloxifene at therapeutic concentrations could modulate 
vascular tone in myogenically active vessels. The present study therefore aimed to 
investigate roles of endothelium, estrogen receptors, Ca^^ channel antagonism, and sex 
difference in acute and chronic vasorelaxant effects of raloxifene in normotensive and 
hypertensive rats. Several approaches were used in order to accomplish these objectives 
and they included isometric force measurement, isobaric diameter measurement, and 
Ca2+ imaging technique in pulmonary and systemic blood vessels. 
The acute effect of raloxifene was investigated in pulmonary arteries and veins 
from male and female Sprague-Dawley rats. In both types of vessels, raloxifene 
induced relaxation which was independent of the presence of endothelium. ICI 182,780 
(estrogen receptor antagonist) failed to influence relaxations to raloxifene. Raloxifene 
reduced CaCb-induced constriction and Ca^^ influx through nifedipine-sensitive Ca^^ 
channels. Raloxifene was less effective in pulmonary veins than arteries. Finally, 
raloxifene induced more relaxation in blood vessels isolated from male than female rats. 
Chronic treatment with raloxifene enhanced the basal release of N O in 
pulmonary arteries from male spontaneously hypertensive rats (SHR) with little effect 
on arteries from normotensive Wistar-Kyoto rats ( W K Y ) . S H R rings with endothelium 
constricted significantly more in response to U46619 than raloxifene-treated S H R rings 
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and this difference was abolished by inhibition of N O synthase or upon the removal of 
endothelium. U46619 or C a C b induced greater constrictions only in rings with 
endothelium from S H R control rats as compared with raloxifene-treated S H R rats. In 
W K Y rings, raloxifene therapy only slightly increased the basal release of N O 
compared with S H R rings. In both S H R and W K Y rings, cumulative addition of 
acetylcholine caused biphasic vascular responses in rings with endothelium, initial 
relaxation at concentration between 3 n M and 10 ^iM followed by subsequent 
constriction in concentrations higher than 30 |aM. In contrast, acetylcholine-induced 
effect was unaffected by raloxifene treatment in each animal group even though the 
difference in acetylcholine-induced relaxation between W K Y and S H R rats tended to 
increase after raloxifene treatment. Raloxifene therapy did not modify endothelium-
independent relaxation to sodium nitroprusside or nifedipine. S H R rings showed 
reduced sensitivity to sodium nitroprusside, which was normalized by raloxifene 
therapy. It was unknown whether therapeutic concentrations of raloxifene could dilate 
smaller blood vessels. Rat resistance-sized mesenteric arteries from S D rats were 
pressurized at 80 m m H g and the dilator effect of raloxifene and estrogen were examined. 
The roles of endothelium and gender were addressed. Raloxifene induced 
vasodilatation at very low concentrations (0.3-30 nM). The dilator effect of raloxifene 
was significantly greater in female arteries than male rings. Long-term oral 
administration of 60 mg/d of raloxifene hydrochloride in w o m e n is expected to result in 
a mean m a x i m u m plasma concentration of 1.36 |j.g/L, equivalent to 2.67 n M of 
raloxifene. The present study shows that the threshold concentration that started to 
induce a dilating effect was around 0.3 n M . Raloxifene-induced vasodilatation was 
markedly reduced after treatment with L - N A M E (NOS inhibitor) and ICI 182,780 
(estrogen receptor antagonist). Likewise, estrogen at low concentrations also dilated rat 
mesenteric arteries, which was inhibited by charybdotoxin plus apamin, but not by L-
N A M E . 
The last set of experiments examined the effect of chronic raloxifene treatment 
on vascular reactivity in female hamsters fed with high cholesterol diet. Twenty-two 
(12-month old) hamsters were used in this study and effects on pressurised (80 m m H g ) 
setpal coronary arteries were studied. The present results show that ovariectomy ( O V X ) 
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tended to reduce ACh-induced vasodilatation in arteries with endothelium from control 
hamsters without affecting pressure-induced myogenic constriction. Chronic raloxifene 
treatment enhanced ACh-induced dilatation in ovariectomized hamsters. O V X enhanced 
U46619-induced vasoconstriction after the development of myogenic tone in arteries 
with endothelium and raloxifene treatment normalized this effect in ovariectomized 
hamsters. Myogenic tone was not affected by 30-min treatment with L - N A M E . 
In summary, the present study has provided some novel findings on the 
vasorelaxant effect of raloxifene in both pulmonary and systemic vascular systems. (1) 
Raloxifene acts primarily on vascular smooth muscle in pulmonary arteries by 
inhibiting Ca^^ entry via L-type Ca^^ channels to cause pulmonary vascular relaxation. 
This action is acute, non-genomic and independent of a functional endothelium or ICI 
182,780-sensitive estrogen receptors. (2) Chronic raloxifene treatment enhanced the 
basal release of N O without affecting acetylcholine-stimulated NO-dependent relaxation, 
and appears to increase vascular smooth muscle sensitivity to exogenous N O in 
pulmonary arteries from S H R rats. (3) Raloxifene, at concentrations equivalent to the 
therapeutic level used to treat osteoporosis in postmenopausal women, potently dilated 
rat resistance mesenteric arteries; this dilatation is likely to be mediated by endothelial 
N O , which is independent of ICI 182,780-sensitive estrogen receptors. (4) Chronic 
raloxifene therapy reduced OVX-induced alterations in agonist-induced constriction in 
septal coronary arteries with endothelium from old female hamsters fed with high 
cholesterol diet. 
The present findings provide experimental evidence for a key mechanism by 
which raloxifene relaxes rat pulmonary vessels by inhibiting Ca^ "^  entry via L-type Ca^^ 
channels on vascular smooth muscle of pulmonary arteries. This calcium antagonistic 
action may make raloxifene a potentially useful agent in the treatment of pulmonary 
arterial hypertension like an oral Ca^^ channel blocker if this effect occurs in vivo. 
Besides, chronic raloxifene therapy augments the basal release of N O in pulmonary 
arteries from spontaneously hypertensive rats. Therapeutic concentrations of raloxifene 
dilates myogenically active resistance arteries in female rats, indicating another 
important mechanism accounting for the vascular benefits of raloxifene. Finally, 
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chronic raloxifene treatment improved OVX-induced increases in vasoconstriction to 
constrictive agonist after the development of myogenic tone in septal coronary arteries 
with endothelium from old female hamsters fed with high cholesterol diet. Taken 
together, the results of this study indicate that raloxifene may be useful in reducing 
vascular tone in both systemic and pulmonary circulation. The outcome of ongoing 
clinical trial of raloxifene on postmenopausal w o m e n at high risks for coronary heart 
disease will determine long-term efficacy and safety. 
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Kyoto (WKY)鼠肺動脈只有微小的影響° Raloxifene減低U46619所引致的 
收縮° Raloxifene療法提高肺動脈平滑肌細胞對鈉硝普驢（SNP)的敏感度。然 
而，我們仍未知道治療濃度下的raloxifene(〜3 nM)能否舒張阻力血管。 
、Raloxifene和女性荷爾蒙對SD鼠小腸繁膜動脈有舒張作用° Raloxifene (0.3-30 
nM)舒張阻力血管，其作用於雌性血管爲強°長期口服每日60毫克raloxifene氯 
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化物在婦女體內相等於每公升 1 . 3 6微克的血獎濃度’相等於 2 . 6 7 nM 
raloxifene。本研究顯示’ raloxifene舒張血管的臨界濃度爲0.3 nM。Raloxifene 
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CHAPTER I 
Introduction 
1.1. Selective Estrogen Receptor Modulators (SERMs) 
Selective estrogen receptor modulators (SERMs) are synthetic chemical 
compounds. Although lacking the steroid structure of estrogen (Fig. 1.2.), they contain a 
tertiary structure that enables their binding to estrogen receptors (ERs) with high affinity. 
According to the chronological development, S E R M s can be basically divided into four 
generations. The most popular representatives for the to 4^ '^ -generation S E R M s are 
tamoxifen, raloxifene, arzoxifene and acolbifene, respectively. Their chemical 
structures are presented in Fig. 1.1.a & b. Based on their chemical structures, S E R M s 
can also be separated into different classes such as triphenylethylenes {e.g., tamoxifen, 
toremifene), benzothiophenes {e.g., raloxifene, arzoxifene), benzopyrans {e.g., 
acolbifene), as well as naphthalenols (e.g., lasofoxifene). 
By binding to ERs, each S E R M has its unique tissue-specific effects distinct from 
estradiol, acting as an estrogen against in some tissues and as an antagonist in others. 
For example, tamoxifen, a 1 ^'-generation S E R M , exerts predominate estrogen 
antagonistic effects in the breast, partial estrogen agonist activity in the bone, 
cardiovascular system and central nervous system (CNS), and predominant estrogen 
agonistic effects in the uterus, liver, and vagina (Love et al, 1992; Shewmon et al, 
1994; Anker et al., 1995; Grey et al. 1995; Chang et al, 1996; Powles et al., 1996; 
Bergman et al, 2000; Jordan, 2001; Ellmen et al., 2003). Raloxifene, a 2"'^-generation 
S E R M , acts as an estrogen agonist in skeleton (Delmas et al, 1997; Ettinger et al., 1999) 
and C N S (Wu et al., 1999) but as an antagonist in the breast and uterus (Saitta et al., 
2001b). The general actions of various S E R M s in specific target tissues are tabulated 
in Table 1.1. 
For the available S E R M s , toremifene, tamoxifen and raloxifene have been 
approved by the Food and Drug Administration (FDA) of the United States for clinical 
I 
CHAPTER I - INTRODUCTION / 2 
uses: toremifene for the treatment of advanced breast cancer, tamoxifen for the 
prevention and treatment of breast cancer, especially ER-positive breast cancer, and 
raloxifene for the prevention and treatment of postmenopausal osteoporosis. The 
estrogen agonistic effects of tamoxifen on the uterus and liver increase the incidence of 
uterine cancer and thromboembolic events, keeping it from being pondered as an ideal 
S E R M . Raloxifene, with a greater estrogen agonist activity in bone but a reduced 
activity in the uterus as compared with tamoxifen, has been examined in the Multiple 
Outcomes of Raloxifene Evaluation ( M O R E ) trial and showed its ability, at 60 or 120 
mg/day, to reduce vertebral fractures rate as compared with placebo (Ettinger et al, 
1999; Kanis et al., 2003). N o w , raloxifene is being continuously tested for its 
equivalence to tamoxifen in breast cancer risk reduction in the Study of Tamoxifen and 
Raloxifene (STAR) sponsored by the National Cancer Institute (NCI). 
I 
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Fig. 1.1a. 
Chemical structures of tamoxifen (a 1®^-generation S E R M ) and raloxifene (a 
2nd-generation SERM). 
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1.1.1. Raloxifene 
Raloxifene (also referred to in literature as L Y 156,758, keoxifene, LY 
139,481-HCL, or Evista®), with generic name "raloxifene hydrochloride", is a 
2"'^-generation S E R M with a non-steroidal benzothiophene chemical structure as shown 
in Fig. 1.1a. It was first discovered in 1987 and found to exert estrogenic effects in 
preventing bone loss in ovariectomized rats (Jordan et ai, 1987) and later was approved 
by the F D A in the United States on 10 December 1997 for the prevention and, 
subsequently, treatment of osteoporosis by stimulating calcium (Ca^^) uptake in the 
bone (Ettinger et ai, 1999; Cummings et al, 1999). 
Raloxifene is intended for long-term use for the prevention and treatment of 
osteoporosis in postmenopausal women. Oral administration of 60 mg/day is 
recommended without regard to meals (Eli Lilly and Company Limited, Basingstoke, 
England) and it is expected to result in a mean maximum plasma concentration of 1.36 
)ig/L (Snyder et al, 2000; Morello et ai, 2003), equivalent to 2.67 nmol/L of raloxifene 
(Tsang et al. 2004b). After oral administration, approximately 60 % of an oral dose is 
absorbed and the absolute bioavailability of raloxifene is 2 % . It is metabolized 
primarily through hepatic glucuronidation and has a half-life of approximate 28-hour 
(Eli Lilly and Company Limited, Basingstoke, England). 
Being an estrogen agonist in bones, raloxifene was examined for the prevention of 
osteoporosis in a 4-year M O R E trial. This was a multi-centered, randomized, 
placebo-controlled study of raloxifene 60 or 120 mg/d versus placebo in 7,705 
osteoporotic postmenopausal women. Results showed that raloxifene at both 
concentrations significantly reduced vertebral fractures rate at 3 years compared to 
placebo (Ettinger et al, 1999; Kanis et ai, 2003). Secondary analysis of the trial also 
indicated a significant reduction (60-70 % ) in the incidence of breast cancer in w o m e n 
randomly assigned to raloxifene (Cummings et al., 1999; Cauley et al” 2001). 
T w o thirds of the participants in the M O R E trial took a 4-year extension trial of 
raloxifene versus placebo, which was entitled the "Continuing Outcomes Relevant to 
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Evista (CORE)" trial. Results revealed that breast cancer reduction in the 
raloxifene-treated group continued over the entire 8-year period with an overall relative 
reduction of 58 % in M O R E plus C O R E (Fabian et al, 2005). Nevertheless, it is 
difficult to attribute the results to a direct effect of continuing raloxifene for another 4 
years or a carry-over effect from the initial 4 years. 
Raloxifene is now being tested for its potential cardioprotective effects for 
postmenopausal w o m e n in the Raloxifene Use for the Heart ( R U T H ) trial in which 
10,000 w o m e n were randomly assigned to 60 mg/day of raloxifene or placebo. The 
incidence of myocardial infarction will be of primary concern, while the cases of breast 
cancer and osteoporotic fractures will also be addressed (Blumenthal et al, 2004). At 
the same time, the equivalence of raloxifene to tamoxifen in breast cancer risk reduction 
is also under investigation in the Study of Tamoxifen and Raloxifene (STAR). Results 
are expected to be announced at the end of year 2005. 
1.2. Mechanisms of Action of SERMs in Vascular System 
S E R M s , like estrogen, bind with high affinity to ERs. After binding to ERs, they 
exhibit either estrogen agonistic or antagonistic effect on specific target tissues. To 
explore the mechanisms of action of S E R M s in vascular system, estrogen and ERs must 
first be introduced. 
1.2.1. Estrogen 
Estrogen, a sex steroid hormone found in mammalian systems, is a lipid derived 
from cholesterol (Fig. 1.2.). The major estrogens produced in w o m e n are estradiol 
(17P-Estradiol, E2), estrone (Ei), and estriol (E3). A m o n g them, estradiol is the major 
secretory product of the ovary. Though some Ei is produced in the ovary as well, most 
El and E3 are formed in the liver from estradiol or in peripheral tissues from 
-androstenedione and other androgens. 
Estrogen is important in both men and w o m e n for regulating a wide range of 
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physiological processes. Especially, estrogen participates in growth, differentiation, 
and maintenance of the functional reproductive system, including the m a m m a r y glands, 
uterus, vagina, and ovaries in females, as well as the testis, epididymis, and prostate in 
males. Besides, estrogen also exerts an anabolic effect on protein metabolism. 
In women, the beneficial effect of estrogen becomes most prominent when the 
circulating 17p-estradiol level drops drastically as w o m e n enter menopause. After 
menopause, ovulation and cyclical elevation in the plasma concentrations of estrogen 
and progesterone stop, while the accompanying pituitary gonadotrophin level increases. 
These hormonal changes are associated with the loss of menstruation and a number of 
symptoms related to a rapid decline in the plasma estrogen levels. 
1.2.2. Estrogen Receptors (ERs) 
A n E R comprises a C- or DNA-binding domain (DBD), a carboxy-terminal E/F- or 
ligand-binding domain (LBD), an N-terminal constitutive ligand-independent but 
cell-type and gene-specific activation function 1 (AF-1) and a C-terminal 
ligand-dependent activation function 2 (AF-2) as shown in Fig. 1.3. 
The D B D contains a two-zinc finger motif important for D N A sequence-specific 
receptor binding to an estrogen response element (ERE) and receptor dimerization 
(Umesono and Evans, 1989; Schwabe et al, 1993; Giguere, 1999; Beato and Klug, 
2000). The L B D mediates ligand binding, receptor dimerization, nuclear translocation, 
and transactivation of target gene expression via the second, ligand-dependent, 
activation function 2 (AF2) (Berry et al., 1990; Danielian et al., 1992; Tzukerman et al, 
1994; Shibata et al, 1997; Cowley and Parker, 1999; Giguere, 1999; M a k et al., 1999; 
Beato and Klug, 2000). AF-1 and AF-2 activate transcription in a cell and promoter 
context specific manner. AF-1 is responsible for the promoter-specific transcription 
activation independent of the presence of ligand, while AF-2 provides ligand-specific 
activation. . 
ERs have two isoforms, namely E R a and ER(3. The cloning of E R a , the first ER, 
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was published in 1986 (Green et al, 1986; Greene et al, 1986). ER(3 was reported 10 
years later (Kuiper et al, 1996). Unique chromosomal localization not only confirmed 
that E R a and ER(3 emanate from the same gene through differential splicing, but also 
showed that the human E R a gene and E R p gene are localized to the long arm of 
chromosome 6 and 14 respectively (Enmark et al, 1997). In human, E R a is 
595-amino acid long, whereas ER(3 contains only 530 amino acids. These two 
i so forms differ mostly in their N- and C-terminal domains that they share only 18 % 
amino acid identity (Fig. 1.2). The marked difference in N-terminal domain indicates 
distinct patterns of the transcriptional activation of different estrogen-responsive genes 
by E R a and E R p (Paech et al, 1997). 
ERs distribute widely throughout human body. E R a to E R p ratio varies on 
different tissues. Table 1.2. illustrates the respective predominant ERs on individual 
tissue type. In particular, in vascular system, E R p predominates in blood vessels, 
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1.2.3. General Mechanisms of Action of SERMs 
S E R M s exert either estrogen agonistic or antagonistic effect on specific target 
tissues. This activity is primarily monitored by the preferential binding of coactivator 
or corepressor transcriptional proteins to the S E R M / E R nuclear receptor transcription 
complex (Horwitz et al, 1996; Brzozowski et ai, 1997; MacGregor and Jordan, 1998; 
Fuqua et al., 2000). 
W h e n a S E R M binds to an ER, a unique conformational change of the receptor 
takes place, causing differential stimulation or inhibition of the activation function (i.e.. 
AF-1 and AF-2) (Howell et al, 2001; Bentrem et al., 2003). These factors interact 
with coactivator and corepressor transcriptional proteins to modulate receptor 
dimerization and subsequent gene transcription. This is basically the same mechanism 
by which estrogen takes its action. W h e n estrogen binds to an E R , a conformational 
change of the receptor occurs so that helix 12 is repositioned, exposing multiple 
coactivator sites. Coactivator binding then initiates a full estrogen agonist 
transcription at both activation function AF-1 and AF-2 (Howell et al, 2001; Bentrem et 
al, 2003). 
Nevertheless, estrogen agonistic or antagonistic effects are also dependent on the 
tissue-specific type and the amount of ERs (Table 1.2.) available for ligand binding as 
well as the type of target gene promoter, estrogen response element (ERE), and 
activating protein-1 (AP-1) (Migliaccio et ai, 1993，1996; Montano et al,, 1995; Endoh 
et al, 1997; Paech et al, 1997; Smith et al, 1997; Lavinsky et al, 1998; Lee et al.’ 
1998; Shiau et al, 1998; Hall and McDonnell, 1999; Speirs et al, 1999; Goldstein et al., 
2000; Hong and Privalsky, 2000; Osborne et al., 2000; Pettersson et al, 2000; Allred et 
al, 2001; Wijayaratne and McDonnell, 2001; Carroll et al., 2003; Clarke et al., 2003; 
Osborne et al., 2003; Razandi et al, 2003; Shaaban et al., 2003). In addition, the 
relative levels of coactivators and corepressors in the nucleus m a y also determine the 
agonist/antagonist activities of a S E R M (Smith et al, 1997; Clarke et al., 2003). The 
levels of coactivators are increased by activation of the M A P K pathway (Smith et al, 
1997). 
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To summarize, the tissue-specific response of a S E R M depends on the following 
factors: (1) the drug's structure and pharmacological properties; (2) the target tissue's 
ERa:ER|3 ratio; (3) whether target genes are activated by E R E or an AP-1 transcription 
complex; and (4) the level of M A P K activity (Lavinsky et al, 1998; Hong and Privalsky, 
2000; Carroll et al., 2003; Osborne et al., 2000，2003). 
1.2.4. Actions of Raloxifene 
The exact mechanisms of action of raloxifene are still unclear (Bryant, 2001). 
However, there are a number of possible genomic and nongenomic pathways that can be 
activated by the interaction of raloxifene with cell membrane or intracellular nuclear 
receptors. Raloxifene binds to and interacts with the E R . It has a high affinity for the 
E R both in m a m m a r y tumor cell lines (Glasebrook et al., 1993) and uterine cytosol 
(Brown and Goldstein, 1980; Szego and Roberts, 1953). Ligand binding of raloxifene 
to the E R leads to unique conformational changes of the receptor that, in turn, stimulate 
AF-l and AF-2. These two factors interact with coactivator and corepressor 
transcriptional proteins that modulate receptor dimerization and gene transcription. 
W h e n raloxifene binds to the ER, helix 12 shifts rightward to block the AF-2 site, 
coactivator binding and subsequent gene transcription are thus initiated (Wijayarantne et 
al, 1999). Nevertheless, the complete story of raloxifene's interaction with ERs, and 
other potential gene transcription comodulators is yet to be elucidated. 
1.3. Effects of SERMs in Cardiovascular System 
Through different mechanisms of actions, S E R M s have been shown to exert 
estrogen-related beneficial effects in the cardiovascular system. For example, 
tamoxifen and raloxifene significantly reduce total cholesterol and low-density 
lipoprotein (LDL) cholesterol, especially in w o m e n with hypercholesterolemia (Delmas 
et al., 1997; Walsh et al., 1998). They also inhibit the oxidation of L D L , a process that 
is implicated in foam cell formation and atherosclerotic progression (Guetta et al., 1995; 
Zuckerman and Bryan, 1996). The plasma levels of fibrinogen, plasminogen activator 
inhibitor-1 (PAI-1) (Walsh et al, 1998), homocysteine (Cattaneo et al., 1998; Mijatovic 
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et al, 1998) and C-reactive protein (CRP) (Paul et al., 1998) are all reduced by 
tamoxifen and raloxifene. These benefits make S E R M s become promising agents for 
the prevention and treatment of cardiovascular diseases, especially in postmenopausal 
w o m e n . 
With the potential benefits in the cardiovascular system, the safety profile of 
raloxifene is of paramount concern. With raloxifene therapy, there is no 
histopathological evidence of endometrial stimulation or increased risk of endometrial 
cancer. Raloxifene actually reduces the incidence of all breast cancers by 62 % , 
invasive breast cancer by 72 % , and invasive ER-positive breast cancer by 84 % 
(Cauley et al., 2001). Venous thromboembolic risk, which also appears in 
postmenopausal w o m e n w h o take estrogen, is the only most substantial side effect for 
the use of raloxifene. To test the clinical aspects of raloxifene in the cardiovascular 
system, the Raloxifene Use for the Heart ( R U T H ) trial has been launched since 2000 
(Mosca, 2001 ； Wenger et al, 2002) and is expected to be completed in late 2005. 
S E R M s were developed aiming at replacing estrogen-containing H R T after 
publication of the large clinical trial (Rossouw et al., 2002) that showed postmenopausal 
w o m e n taking H R T actually had higher incidences of heart attack and stroke. 
1.3.1. Effects of SERMs on Endothelial Function 
S E R M s exert both genomic and non-genomic effects on vascular reactivity. 
Non-genomically, both tamoxifen and raloxifene acutely dilated blood vessels by 
increasing the production of nitric oxide (NO), which is mediated by endothelial N O 
synthase (eNOS) (Simoncini and Genazzani, 2000; Simoncini et al., 2002; Hisamoto et 
al., 2001; Figtree et al., 1999，2000), an enzyme that catalyzes the formation of N O 
from the precursor, L-arginine in endothelial cells. By diffusion, N O reaches nearby 
smooth muscle cells and activates the soluble form of guanylate cyclase (GC) to elevate 
the intracellular cyclic ‘ G M P (cGMP) levels. The c G M P acts through 
cGMP-dependent protein kinase (PKG) to relax smooth muscle and cause 
vasodilatation via multiple mechanisms, many of which lead to reduced intracellular 
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Ca2+ concentrations. The NO-dependent relaxant effect is likely to be mediated by 
ERs because the relaxation was inhibited by a classical E R antagonist ICI 182,780 
(Simoncini and Genazzani, 2000; Figtree et al, 1999). B y promoting the interaction 
between E R a and phosphatidylinositol 3-kinase (PI3K), raloxifene rapidly activates 
e N O S and stimulates N O production in cultured human umbilical vein endothelial cells 
(Simoncini et al., 2002). Raloxifene therapy is associated with a positive modulation 
of endothelium-dependent vasodilatation likely due to an improved N O bioavailability 
(Colacurci et al, 2003). 
Genomically, chronic raloxifene treatment improved endothelium-derived N O 
release by increasing e N O S rtiRNA expression (Rahimian et al., 2002). After chronic 
raloxifene therapy, the e N O S activity was up-regulated as reflected by an increased 
bioavailability of N O (Wassmann et al., 2002). In addition, the raloxifene analogue, 
LY117018, when administered orally or subcutaneously, augmented 
endothelium-dependent vasorelaxation of aortic rings in ovariectomized rats (Rahimian 
et al, 1997). The increased basal and receptor-mediated release of N O has been 
proposed to contribute to enhanced vasodilatation. These findings, together with the 
inhibition of cell adhesion molecule expression by raloxifene (Simoncini et al, 1999), 
may benefit the overall vascular function. 
In ovariectomized rats (Pavo et al., 2000), impaired vasodilatation is probably 
related to the down-regulation of c N O S (constitutive NOS), causing enhancement of 
vasoconstriction to vasopressin. This effect can be reversed by raloxifene treatment. 
Raloxifene decreased systemic and coronary vascular resistance, and increased uterine 
and coronary blood flow in ovariectomized sheep (Clark et al., 2000). These findings 
indicate that the improvement in the coronary circulation might serve as evidence for 
the cardioprotective effect of raloxifene. In ovariectomized ewes, raloxifene caused 
short-term increases in both coronary and uterine blood flow, which is similar to the 
effect of estrogen. Systemic administration of a N O S inhibitor, N^-nitro-L-arginine 
‘methyl ester (L-NAME), partially reversed the effect, implying an involvement of N O 
(Zoma et al., 2000). However, whether the effects in ovine vessels can be extended to 
human circulatory system is yet to be verified. Randomized studies of raloxifene in 
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aged ovariectomized ewes showed a greater coronary artery dilatation at angiography in 
response to raloxifene, whereas there was no difference in vascular remodeling (Gaynor 
et aL, 2000). 
In vasculopathic male rats (Russell et aL, 2001), the vascular effects were 
compared between LY117018 and 17P-ethinyloestradiol. LY117018 inhibited 
adrenergically mediated vasoconstriction and reduced blood pressure via both 
NO-dependent and independent mechanisms. Ethinyloestradiol increased triglyceride 
level and modestly decreased cholesterol ester level. In contrast, L Y 117018 had no 
effect on triglycerides but decreased the total plasma cholesterol esters. 
1.3.2. Effects of SERMs on Vascular Smooth Muscle 
Raloxifene relaxed rabbit coronary arteries probably via inhibition of vascular Ca^^ 
channels (Figtree et al； 1999). L Y 117018，like 17(3-estradiol，inhibited Ca^^ channels 
in vascular myocytes from rat aortas (Cohen and Susemichel, 1996) but with higher 
effectiveness than estrogen. Tamoxifen inhibited the activity of protein kinase C 
(PKC) (Wickman and Vollrath, 2000) and voltage-sensitive Ca^^ channels (Song et al, 
1996); both could lead to vasorelaxation. Recently, this laboratory has provided the 
first line of evidence for a direct inhibitory action of raloxifene on L-type 
voltage-sensitive Ca^^ channels in myocytes isolated from rat cerebral arteries (Tsang et 
al, 2004b), on nifedipine-sensitive L-type Ca^^ channels in rat pulmonary arteries and 
veins (Chan et al, 2005), and on ICI 182,708-insensitive Ca^^ channels in rat intrarenal 
arteries (Leung et al, 2005). It appears that endothelium (NO)-independent 
vasorelaxation to raloxifene in vitro is primarily mediated by inhibition of extracellular 
Ca^^ entry in vascular smooth muscle ( V S M ) cells. 
In human aortic smooth muscle cell cultures (Wiernicki et aL, 1996), raloxifene, 
like 17(3-estradiol, inhibited V S M cell migration without affecting proliferation. 
-LY117018 inhibited Ca^^ channels in V S M cells of rats (Cohen and Susemichel, 1996). 
As compared with estrogen, LY117018 is a more potent Ca'^ channel antagonist. In a 
rat aortic V S M cell preparation (Silfani et al, 2001), chronic treatment with estrogen, 
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raloxifene and tamoxifen prevented angiotensin Il-induced release of arachidonic acid 
(AA) coupled to inhibition of mitogenesis. 
1.4. Effects of Raloxifene on Vascular Circulations 
The circulatory system comprises systemic and pulmonary circulations. The 
pulmonary circulation allows the passage of blood from the right side of the heart 
through arteries to the lungs where it picks up oxygen and is returned to the left side of 
the heart by veins. The oxygenated blood is then being pumped by the left ventricle of 
the heart into the systemic circulation, which is parceled out in various proportions to 
the systemic organs through a parallel arrangement of vessels, ensuring all organs 
receive blood of the same composition. 
The modulation of vascular tone by raloxifene has been studied in the systemic 
circulation. A few research groups examined the effect of estrogen on the pulmonary 
artery (Gonzales et al., 2001; Saetrum et al” 2002). However, no studies have by far 
examined the effects of S E R M s on vasomotor activity in the pulmonary vascular 
circulation before Chan et al. (2005). 
1.4.1. Effects of Raloxifene on Systemic Circulation 
1.4.1.1. Preclinical Data 
1.4.1.LI. Effects on Serum Lipids 
Raloxifene reduced serum cholesterol levels in ovariectomized rats (Black et al, 
1994). The degree of bone loss was alleviated while stimulatory effect on the uterine 
endometrium was absent after raloxifene therapy. The reduction of serum cholesterol 
levels was dependent on the dosage and the duration of the treatment (Kauffman et al., 
1997). In rats, raloxifene, like estradiol, lowered high density lipoprotein (HDL). In 
cultured human liver HepG2 cells (Hozumi et al, 2000), however, raloxifene did not 
increase intracellular triglyceride levels. 
V. 
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1.4.1.1.2. Effects on Inflammation Markers and Blood Coagulation 
In ovariectomized rats (Glasebrook et al, 1995)，raloxifene caused an increase in 
serum interleukin-6 levels. The ovariectomy-induced osteopenia was concomitantly 
attenuated by raloxifene. In human umbilical vein endothelial cells (Richardson et al., 
2000), through the up-regulation of thrombomodulin, the anticoagulant activities of 
both the unstimulated and the interleukin 1-activated endothelial cells were enhanced by 
raloxifene. In cultured human saphenous vein endothelial cells (Simoncini et al, 
1999), raloxifene inhibited endothelial vascular cell adhesion molecule (VCAM)-l 
expression, indicating a specific anti-atherogenic activity of raloxifene on vascular wall 
via inhibition of V C A M - 1 expression and the interactions between endothelium and 
leucocytes. 
1.4.1.1.3. Antioxidative Effects 
Inhibition of L D L oxidation was implicated in foam cell formation and 
atherosclerotic progression (Guetta et al, 1995; Zuckerman and Bryan, 1996). 
Raloxifene was proved to protect L D L against oxidation with higher potency than 
17(3-estradiol (Zuckerman and Bryan, 1996). This effect is likely to contribute to the 
cardioprotective properties of raloxifene. 
1.4.1.1.4. Effects on Nitric Oxide and Endothelial Function 
In aortic rings isolated from ovariectomized rats treated with oral administration or 
with subcutaneous pellet delivery agents (Rahimian et al, 1997), raloxifene analogue, 
LY117018，augmented the endothelium-dependent vasodilatation. The increase in 
basal and receptor-mediated release of N O is the mechanism underlying the enhanced 
endothelium-dependent vasodilatation. In coronary artery rings from both male and 
female rabbits (Figtree et al., 1999), raloxifene induced a substantially greater 
endothelium-dependent relaxation than estrogen. This endothelium- and 
ER-dependent effect is mediated by N O , while endothelium-independent relaxation is 
mediated by direct Ca^ "^  antagonism. 
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As mentioned in section 1.3.1.，the enhanced vasoconstriction to vasopressin due to 
the down-regulation of c N O S was reversed by raloxifene (Pavo et al., 2000). 
Raloxifene also decreased systemic and coronary vascular resistance, and increased 
uterine and coronary blood flow in ovariectomized sheep (Clark et al., 2000). A study 
on ovariectomized ewes (Zoma et al, 2000) reported that raloxifene produced 
short-term increases in coronary and uterine blood flow. In insulin-resistant male rats 
(Russell et al, 2001)，LY117018 (a raloxifene analogue) inhibited adrenergically 
mediated vasoconstriction and reduced blood pressure via both NO-dependent and 
-independent mechanisms. 
In human umbilical vein endothelial cell culture (Simoncini and Genazzani, 2000), 
raloxifene induced a rapid N O production that was dependent on an ER-mediated 
mechanism; raloxifene did not increase N O release via a transcriptional increase of 
e N O S . This m a y account for another direct vascular protective effect of raloxifene. 
1.4.1.1.5. Effects on Vascular Smooth Muscle 
Effects of raloxifene on V S M are described in section 1.3.2. for convenient 
reference. 
1.4.1.1.6. Vascular Injury, Atherosclerosis and Ischaemia-Reperfusion Injury 
Raloxifene treatment inhibited cholesterol accumulation in aorta in ovariectomized 
cholesterol-fed rabbits (Bjarnason et al, 1997). This was partly caused by favorable 
changes in serum lipids and lipoproteins. In ovariectomized cynomolgus monkeys fed 
with a moderately atherogenic diet in the presence of conjugated equine estrogen (CEE) 
(Clarkson et al., 1998), a significant reduction in coronary artery plaque size was 
observed. Raloxifene, however, neither at low nor high doses, affected the size of the 
atherosclerotic plaque. This may due to the fact that E R a and E R P signal in opposite 
.ways when complexed with the natural hormone estradiol from an A P I site: with E R a , 
17p-estradiol activated transcription, whereas with ER(3, 17(3-estradiol inhibited 
transcription. However, raloxifene activates transcription with ER(3 at an A P I site 
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(Paech et al, 1997). This probably explains why the size of plaque was reduced with 
treatment with estradiol but not with raloxifene. 
Raloxifene inhibited balloon carotid arterial injury via direct effects on the vascular 
wall, which involved the E R and were partially independent of changes in serum 
cholesterol levels in male and ovariectomized female rats (Kauffman et al., 2000). 
To examine aortic atherosclerosis in ovariectomized cholesterol-fed rabbits 
(Bjarnason et al., 2000), high doses of raloxifene were used. The plasma 
concentrations of raloxifene in the rabbits were similar to those in raloxifene-taking 
post-menopausal w o m e n (Bjarnason et al., 2000). At increasing dosage, raloxifene 
inhibited aortic atherosclerosis compared with placebo, with the inhibition only partly 
explained by the difference in serum lipid levels. Raloxifene significantly reduced the 
progression of atherosclerosis versus placebo in the rabbits. 
1.4.1.2. Clinical Studies - Effects in Post-Menopausal Women 
1.4.1.2.1. Effects on Serum Lipids, Lipoproteins and Triglycerides 
A study (Delmas et al., 1997) involved 601 postmenopausal w o m e n with low and 
normal bone mineral density, who randomly received 30, 60 or 150 mg/d of raloxifene 
versus placebo. After 24 months, raloxifene dose-dependently reduced the serum 
concentrations of total and L D L cholesterol. While estrogen increased the 
concentrations of H D L cholesterol and triglycerides, raloxifene did not affect them at all. 
In another study on 390 healthy postmenopausal w o m e n randomized to 60 or 120 
mg/day of raloxifene (Walsh et al” 1998), raloxifene decreased the plasma levels of 
L D L cholesterol, fibrinogen and lipoprotein, and increased the levels of 
HDL2-cholesterol, but did not affect the levels of triglyceride. 
The atherogenic risk factors non-HDL cholesterol and apo-B/apo-Al were lowered 
by raloxifene as compared with placebo. The effect was the greatest in w o m e n with 
baseline hypercholesterolaemia (total cholesterol > 240 mg/dl) (Anderson et al, 2001). 
V 
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Another 56 healthy postmenopausal w o m e n aged 45 - 60 years with hysterectomy 
underwent a 2-year randomized therapy with 60 or 150 m g of raloxifene, conjugated 
equine estrogen (CEE) (0.625 mg) or placebo daily. The results showed a benefit of 
taking raloxifene, similar to C E E , in reducing L D L cholesterol and fibrinogen levels (de 
Valk-de Roo et al., 1999). However, increases in H D L cholesterol and decreases in 
PAI-1 were observed in C E E users but not in raloxifene users. Increases in the 
concentrations of cardiovascular risk factors C R P levels and triglyceride were also not 
seen in raloxifene. 
In two parallel, double-blind, randomized, placebo-controlled osteoporosis 
prevention trials (Johnston et al., 2000), totally 1,145 healthy European and North 
American post-menopausal w o m e n were randomly assigned to take 30, 60 or 150 
mg/day of raloxifene hydrochloride versus placebo. Raloxifene preserved bone 
mineral density at important skeletal sites and reduced L D L cholesterol levels without 
changing H D L cholesterol or triglyceride concentrations (Johnston et aL, 2000). 
Sustained benefit on serum levels of lipids and fibrinogen of taking raloxifene was 
reported in the M O R E trial. Again, raloxifene did not increase the levels of serum 
triglycerides in osteoporotic postmenopausal w o m e n or in subjects with baseline 
hypertriglyceridaemia or diabetes. 
1.4.1.2.2. Effects on Inflammation Markers and Homocysteine 
The estrogenic effects of raloxifene on atherogenic lipoproteins m a y reduce 
vascular inflammation markers, leading to an anti-atherogenic consequence. In a study 
on 23 healthy postmenopausal women, each was randomly assigned to receive 
raloxifene 60 mg/day, C E E 0.625 mg/day or placebo daily for a month (Blum et al., 
2000). Raloxifene reduced the levels of cell adhesion molecules, though to a lesser 
extent than C E E . Nonetheless, raloxifene did not increase other inflammation markers 
as seen in C E E , specifically C R P and matrix metalloproteinase-9 (MMP-9). 
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1.4.1.2.3. Effects on Coagulation Markers 
Raloxifene, 60 or 120 mg/day, decreased fibrinogen in healthy postmenopausal 
w o m e n w h o received treatment for 6 months (Walsh et al, 1998) and in 
hysterectomized subjects who received treatment for 24 months (de Valk-de Roo et al., 
1999) compared to those receiving C E E . The effects of raloxifene on PAI-1 and tissue 
plasminogen activator (tPA) were inconsistent. PAI-1 was decreased by treatment with 
60 mg/day raloxifene but it was increased by treatment with 150 mg/day raloxifene for 
24 months. L o w dose of raloxifene (60 mg/day) reduced, but high dose (150 mg/day) 
elevated tPA levels. 
1.4.1.2.4. Effects on Endothelial Function 
In a study with postmenopausal w o m e n (Sarrel et al., 2001), brachial artery 
diameter increased significantly after raloxifene treatment as compared with placebo. 
In another trial in postmenopausal w o m e n (Saitta et al, 2001b), raloxifene (60 mg/day) 
significantly improved flow-mediated vasodilatation, raised plasma N O levels and 
reduced plasma endothelin-1 level. However, some other clinical studies showed that 
raloxifene might not improve endothelial function. For example, Duschek et al. (2003) 
demonstrated that raloxifene did not affect endothelium-dependent vasodilatation in 
healthy postmenopausal women. Besides, Christodoulakos et al. (2004) reported that 
raloxifene did not increase the circulating vascular endothelial growth factor (VEGF) in 
postmenopausal w o m e n . 
1.4.1.2.5. Cardiovascular Events 
In M O R E study (Ettinger et al, 1999), raloxifene significantly decreased the total 
and L D L cholesterol (Harper et al., 2000) and fibrinogen levels without affecting the 
H D L cholesterol or triglyceride levels. In the following 3 years, the total numbers of 
coronary and cerebrovascular events were not significantly different across treatment 
groups except for the number of coronary events, including myocardial infarction, 
unstable angina, or coronary ischemia, in year 2 in the raloxifene 120 mg/day group. 
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In w o m e n with documented coronary heart disease ( C H D ) in the M O R E study, 
cardiovascular event was not exacerbated (Barrett-Connor, 2001). Although raloxifene 
therapy did not significantly affect the cardiovascular risk in the overall cohort, there 
was a significant reduction in the cardiovascular risks in w o m e n characterized as being 
at increased risk of having cardiovascular problems. Also, there was no evidence 
showing any early increased cardiovascular events, including coronary events 
(myocardial infarction, unstable angina, or coronary ischemia) and cerebrovascular 
events (stroke or transient ischemic attack), in w o m e n with high cardiovascular risk 
(Barrett-Connor et al, 2002). A n average decrease in total levels of cholesterol and 
L D L cholesterol by about 8 and 12 % , respectively, was reported after raloxifene 
therapy. In contrast to estrogen, raloxifene did not increase H D L cholesterol or 
triglyceride levels. 
1.5. Myogenic Response and Vascular System 
Myogenic response (or myogenic tone) refers to an active decrease in vessel 
diameter after increasing transmural pressure, or to an increase in diameter after 
reducing the pressure. Bayliss first described this vasomotor phenomenon in 1902 
(Bayliss, 1902). Myogenic response provides a basal tone for arterioles to adjust their 
diameters in response to any neurohumoral stimuli. This autoregulation mechanism 
controls the basal peripheral vascular resistance and capillary hydrostatic pressure 
(Johnson, 1981; Davis and Hill, 1999) to ensure a constant blood flow over a wide 
range of pressures. Such a mechanism is particularly important in the brain, heart and 
kidneys (Johnson, 1989; Muller et al, 1996; Farad et al., 1989; R o m a n and Harder, 
1993). The myogenic response in some small veins (Davis et al, 1992; Berczi et al,, 
1992; Kuo et ai, 1993; Dornyei et al, 1996) is relatively weak and not well 
investigated. O n the contrary, many studies have 丨investigated the myogenic response 
of small arteries and arterioles that are important for the regulation of blood pressure 
and blood flow distribution to several major organs. 
- • 
The myogenic response is the greatest in blood vessels with intermediate diameter. 
It is relatively weak in either larger or very small vessels. This was indicated in in 
CHAPTER I - INTRODUCTION / 25 
vitro investigations of the vascular bed of rat mesenteric arteries (Sun et al., 1992), rat 
skeletal muscle arteries (Sun et al, 1994)，rabbit renal arteries and arterioles (Edwards , 
1983)，pig coronary arteries and arterioles (Liao and Kuo, 1997)，arterioles of the 
hamster cheek pouch (Davis, 1993), human pial small arteries (Thorin-Trescases et al., 
1997), and human coronary small arteries (Miller et al., 1997). Apart from arteries, 
myogenic behavior has been also documented in isolated rabbit facial veins (Henrion et 
al., 1997) and lymphatic circulation (Zawieja, 1996). Moreover, the strength of 
myogenic responses depend on individual vascular bed. For example, rat small 
cerebral (Osol et aL, 1991) and skeletal muscle (Watanabe et al., 1993) vessels have a 
strong myogenic response, whereas a weak myogenic response was observed in similar 
sized mesenteric vessels. 
1.5.1. Initiation and Development of Myogenic Response 
The pressure-induced alternation of vessel wall tension is probably the stimulus for 
the myogenic constriction (Johnson, 1989), which is strongly supported by a study 
showing that vessel reactivity to agonists is based on the accompanying changes in 
vessel wall tension (VanBavel and Mulvany, 1994). Furthermore, the intracellular 
Ca2+ concentration and the levels of myosin light chain ( M L C ) phosphorylation have 
been suggested to be correlated with vascular wall tension (Zou et al., 1995) and 
involved in myogenic responses (Fig. 1.5a). 
The myogenic response is primarily controlled by stretch. Studies using the 
myogenically reactive rabbit facial vein showed that stretch activates Ca^^ influx (Laher 
et al., 1988). Stretch-activated cation channels (SACs) are located on V S M cell 
plasma membrane. T w o roles for SACs in causing muscle contraction were proposed 
by Zou et al. in 2002: (i) passing cations (mainly Na+) leading to membrane 
depolarization and subsequent activation of voltage-gated Ca^^ channels (VGCCs), and 
(ii) passing Ca^^ to increase the cytosolic [Ca^^] either directly or indirectly by 
triggering Ca^^ release from Ca^ "^  stores. The involvement of V G C C s is confirmed by 
studies showing that the myogenic tone was abolished by inhibitors of V G C C s (Knot 
and Nelson, 1995; Kotecha et al； 2000; Setoguchi et al., 1997; Wesselman et al, 1996). 
I 
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The development of myogenic tone may be conveniently divided into 3 distinct 
phases as suggested by Osol et al. in rat posterior cerebral artery (Osol et al, 2002). 
Phase 1, development of the tone, is characterized by substantial membrane 
depolarization, rise of cytosolic Ca^^, constriction, accompanied by a reduction in wall 
tension. Phase 2, myogenic reactivity, involves the maintenance of the tone in the face 
of elevated transmural pressure. Usually, between 60 and 140 m m H g , little change in 
diameter is observed despite wall tension increases significantly. Phase 3, forced 
dilatation, occurs when the transmural pressure goes beyond 140 m m H g at which 
vessels become unsteady and even undergo forced dilatation. This is accompanied by 
the further significant increases in Ca^^ and wall tension, resulting in the complete loss 
of myogenic tone. 
1.5.2. Regulation of Myogenic Response 
1.5.2.1. 20-hydroxyeicosatetraenoic acid (20-HETE) 
For the maintenance of vascular tone, a cytochrome P-450 metabolite, possibly 
20-hydroxyeicosatetraenoic acid (20-HETE) may play a role in the development of 
myogenic tone in rat small mesenteric arteries (Chlopicki et al, 2001). 20-HETE 
activates P K C leading to stimulation of a small G protein rho in V S M cells of cat 
cerebral arteries (Lange et al, 1997). Therefore, P K C , that plays a role in 
Ca2+-contraction coupling notably during pressure-induced adaptations of the vascular 
tone (Wesselman et al., 2001), may also take part in maintaining myogenic tone. 
It has been demonstrated that 20-HETE activates the mitogen-activated protein 
kinase ( M A P K ) pathway in rat aortic V S M cells (Uddin et al., 1998; Muthalif et aL, 
1998). Moreover, it was shown that the 20-HETE-induced proliferation of V S M cells 
and activation of M A P K activity are attenuated by a Ras famesyl transferase inhibitor 
and in cells transfected with a dominant negative Ras (Muthalif et aL, 2001). 
20-HETE appears to couple receptors that activate phospholipases to activation of 
M A P K signal transduction cascade in V S M cells via Ras-dependent manner similar to 
the mechanism previously described by Dulin et al. (1998) and Jiao et al. (1998) for 
other fatty acids in rabbit renal proximal tubule cells. Detailed mechanisms for the 
I 
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vasoconstrictor and mitogenic effects of 20-HETE are shown in Fig. 1.5b. 
1.5.2.2. Protein Kinase C, Rho/Rho-Kinase, and Tyrosine Kinase 
Smooth muscle contraction is modulated by P K C and small GTPase 
Rho/Rho-activated protein kinase (Rho-kinase) pathways (Fukata et al, 2001). In the 
cerebral circulation, P K C plays a role in the regulation of myogenic tone by 
sensitization of myofilaments to Ca〗.. P K C phosphorylates various ion channels by 
augmenting voltage-dependent Ca^ "^  channels and inhibiting K+ channels, where both 
lead to vessel contraction (Fig. 1.5a & b). These actions of P K C amplify vascular 
contractility to different agonists and may be critical in the regulation of cerebral artery 
tone during vasospasm (Laher and Zhang, 2001). In canine basilar arteries, at least 
four isoforms of P K C have been identified (Nishizawa et al, 2000). P K C delta, one of 
the four isoforms found in canine basilar artery, is activated by phosphorylation of its 
tyrosine residues (Denning et al., 1996). Y-27632 (a Rho-kinase inhibitor) inhibited 
the stretch-induced translocation of P K C delta but not in P K C alpha. Therefore, P K C , 
Rho/Rho-kinase, and tyrosine kinase may be involved in the stretch-induced 
contraction. 
Studies also proposed that integrins and herbimycin A-sensitive tyrosine kinases 
such as pp60src might act as a mechanosensor. It takes action via mechano-gated 
channels to elicit membrane depolarization, interacting with each other to form focal 
adhesion plaques. This results in the regulation of transmembrane Ca^ "^  entry through 
L-type V G C C s , contributing to myogenic contraction development in the cerebral artery 
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Fig. 1.5a. 
Main pathways involved in the myogenic tone. 
D A G , diacylglycerol; Em, membrane potential; IP3, inositol 1,4,5-trisphosphate; 
Kca, Ca2+-activated K+ channel; M L C , myosin light chain; M L C K , myosin light 
chain kinase; PKC, protein kinase C; V G C C , voltage-gated Ca^" channels, 
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1.5.3. Myogenic Response and Endothelium 
To examine a role of endothelium in the develop of myogenic tone, the effects of 
endothelium removal were investigated. Several studies in arteries without 
endothelium altered the myogenic response, whereas others showed 
endothelium-independent myogenic tone. For instance, the endothelium was found to 
be involved in the regulation of myogenic response because in an endotheiium-denuded 
vessel the response decreased after applying the perfusate from an endothelium-intact 
and myogenically active vessel segment (Harder et al., 1989); in contrast, endothelial 
cells were not involved in the myogenic property of the mechanically denuded renal 
vessels (Liu et al, 1994). 
To summarize, endothelium plays a role in myogenic response depending on the 
kinds of vessels under investigation. Myogenic tone appears to be dependent primarily 
on the smooth muscle cells within vessel wall but it can be partially modified by the 
endothelium. 
1.5.4. Estrogen and Myogenic Tone 
Pressure-induced constrictions (myogenic tone) were almost 2-fold greater in 
isolated coronary arteries from estrogen-deficient male or ovariectomized ( O V X ) rats as 
compared with their counterparts obtained from female rats or O V X rats receiving 
physiological levels of estrogen replacement ( O V X + E group) (Wellman et al, 1996). 
These discrepancies in coronary artery diameter were abolished by removal of the 
vascular endothelium or chemical inhibition of N O synthase (NOS). This is likely that 
the physiological levels of circulating 17(3-estradiol can elevate basal N O release from 
the endothelial cells, thus increasing the diameter of pressurized coronary arteries. 
Skarsgard et al. in 1997 showed that the chronic exposure of rat middle cerebral 
artery to physiological levels of 17p-estradiol induced an increase in basal N O 
production. Chronic estrogen exposure did not alter artery sensitivity to an N O donor 
or stimulated N O release by a Ca"^ ionophore, arguing against the increased expression 
I 
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of N O S as a mechanism responsible for increased N O release. Chronic estrogen 
treatment did not contribute to the passive distensibility of cerebral arteries in either sex. 
In addition, the net arterial tone was not altered by chronic estrogen exposure despite of 
an increased basal N O secretion, suggesting the presence of compensatory myogenic 
mechanisms that may function to maintain a consistent arterial diameter. 
Another study on Fisher 334 rat middle cerebral artery showed a gender difference 
in the myogenic response (Geary et al., 1998). It appears that circulating estrogen 
decreases myogenic tone indirectly by increasing endothelial N O production. O V X 
resulted in augmented myogenic tone and reduced sensitivity to N O S inhibition that 
was reversed by chronic estrogen treatment. A more recent study on 12-week:-old C57 
Black mice middle cerebral artery (Geary et al., 2000) indicated that inhibition of N O S 
caused significantly greater myogenic tone in arteries from male mice compared with 
arteries from untreated female mice. This gender difference was abolished by O V X 
and restored by estrogen replacement treatment. 
In gracilis muscle arterioles (Huang et al, 1997a) of female spontaneously 
hypertensive rats (SHR), the pressure-induced reduction in vessel diameter of male 
S H R and O V X female S H R arterioles was significantly less than that in arterioles from 
female S H R and O V X female S H R receiving estrogen replacement treatment, 
indicating a greater myogenic tone in male S H R and O V X female S H R . Huang et al. 
also described a similar gender difference in another set of experiments examining 
gracilis muscle arterioles isolated from male, female, O V X female and estrogen-treated 
O V X female Wistar rats (Huang et al, 1997b). 
1.6. Objectives of the Present Study 
After menopause, there is a marked increase of the risk of cardiovascular diseases 
(CVD), such as atherosclerosis, angina, coronary artery disease and stroke. During 
this stage, estrogen is naturally deficient in post-menopausal women. H R T may 
potentially prevent or delay C V D from occurring. In the past decades, 17p-estradiol 
has been shown to be cardioprotective and prescribed as a replacement of the natural 
I 
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estrogen in postmenopausal women. However, the use of H R T after menopause for 
prevention of the long-term complications of estrogen deprivation has been questioned 
after publication of large clinical trials (Hulley et al., 1998; Herrington et al, 2000; 
Rossouw et al, 2002) that failed to confirm overall benefits. Therefore, most w o m e n 
have discontinued H R T due to the increased incidence of breast and uterine cancer, and 
now increased cardiovascular risks. 
Raloxifene, a S E R M possessing target-specific estrogen agonist and antagonist 
properties, has become a new promising synthetic chemical aiming at replacing estrogen 
in post-menopausal w o m e n as it contains beneficial effects of estrogen while avoiding 
some side-effects of H R T . However, the exact mechanisms of vascular action of 
raloxifene in the circulatory system are still incompletely understood. The objectives 
of the present study therefore were to examine: 
(1) The role of gender, endothelium and antagonism of Ca^^ influx in vascular 
responses to raloxifene in the rat pulmonary artery. 
(2) The role of chronic raloxifene treatment in pulmonary artery reactivity of 
spontaneous hypertensive rat (SHR) and Wistar-Kyoto rat (WKY). 
(3) The effects of therapeutic concentrations of raloxifene in the pressurized rat 
mesenteric artery. 
(4) The effects of chronic high-cholesterol diet and raloxifene treatment in 
pressurized hamster septal coronary artery. 
< 
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CHAPTER II 
Methods and Materials 
2.1. Tissue and Cell Preparation 
2.1.1. Vessel Preparation 
All experiments described in this thesis were approved by the Animal Research 
Ethics Committee of the Chinese University of Hong Kong. Investigations conformed 
to the Guide for the Care and Use of Laboratory Animals published by the US National 
institute of Health (NIH Publication No.85-23, revised 1996). Animals used include 
adult male and female Sprague-Dawley (SD) rats (weighing � 2 6 0 - 280 g), adult male 
Wistar-Kyoto (WKY) rats (weighed about 370 - 430 g) and spontaneously hypertensive 
rats (SHR) (weighing � 3 4 0 - 400 g), as well as young and aged female Syrian golden 
hamsters (weighing ~ 100 - 140 g and 120 - 200 g, respectively). They were all 
supplied by the Laboratory Animal Services Center, the Chinese University of Hong 
Kong, Hong Kong, China. 
The animals were euthanized by inhalation of CO2. The SD second-order rat 
intralobal pulmonary arteries, main pulmonary veins, the fourth-order rat small superior 
mesenteric arteries, and the Syrian golden hamster septal coronary arteries were 
carefully dissected out and immersed in freshly-prepared ice-cold (4 °C) and 
oxygenated Krebs-Henseleit solution (composition of Krebs solution described in 
section 2.6.). Under a dissection microscope, the surrounding adipose or connective 
tissues were carefully removed (Fig. 2.1a. - c.). Each artery was cut into 2 - 3 mm wide 
ring segments. One (for the septal coronary arteries), two (for the pulmonary veins) or 
four (for the pulmonary and mesenteric arteries) ring segments were prepared for 
measurement of isometric tension or isobaric diameter. Each experiment was 
performed on rings obtained from different animals. 
4 
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Fig. 2.1a -c. 
Isolation of a rat small mesenteric artery with removal of the surrounding 
adipose or connective tissues with a pair of forceps and scissors. 
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2.1.2. Removal of a Functional Endothelium 
In some experiments, the endothelial layer was mechanically disrupted either by 
gently rubbing the luminal surface of a ring back and forth several times with a tungsten 
wire in the case of isometric tension measurement experiments, or by passing 1 ml 
bubbles through the lumen in diameter measurement experiments. Functional removal 
of the endothelium was confirmed by a lack of relaxation to acetylcholine (ACh) (3 |j,M 
for the pulmonary arteries and veins under isometric conditions and 1 |JM for the 
mesenteric and septal coronary arteries under isobaric conditions). 
2.2. Myograph and Pressure Myograph Setups 
2.2.1. Myograph - Isometric Tension Measurement 
A Multi Myograph System (Danish Myo Technology A/S, Denmark) (Fig. 2.Id.) 
is used to measure changes in isometric force of a ring. A ring segment of 2 mm-long 
mesenteric, pulmonary artery or vein was placed in a bathing chamber filled with 
Krebs-Henseleit solution. The Krebs solution was continuously bubbled with 95% O2-
5% CO2 mixture at 37 °C (pH 7.4). Each ring was suspended between two tungsten 
wires (each with 40 jam in diameter). Each wire was fixed to the mounting jaws of the 
myograph (Fig. 2.1e.). Changes in isometric force were continuously recorded by a 
Maclab software (version 3.6.8) with an aid of a PowerLab/4SP data acquisition system 
(ADInstruments Corporate) connected to a Mac computer. All rings were placed under 
an optimal' resting tension (approximately 1 - 2 mN), which was the minimal level of 
stretch giving the largest force development in 60 mM K+-containing solution as 
determined by a length-tension relationship (Nyhan et al. 2002). 
“ Thirty min after mounting, rings were first constricted by 100 nM U46619 or 1 
I^M phenylephrine (Phe) and subsequently challenged with ACh to verify the presence 
or absence of the endothelium. They were then washed in Krebs solution to restore 
tension to a baseline tone and allowed to stabilize for 60 min before the start of 
experiments. 
CHAPTER II - METHODS AND MATERIALS / 3 7 
2.2.2. Pressure Myograph 一 Isobaric Diameter Measurement 
A Pressure Myograph Setup (Danish Myo Technology A/S, Denmark) is applied 
to measure diameter changes of a vessel cannulated in the chamber under an isobaric 
condition. The whole setup consists of a pressure myograph chamber (Fig. 2.2a.), 
pressure regulator, myo-interface, computer and an inverted microscope. During the 
experiment, the chamber, being placed on the stage of the inverted microscope (Fig. 
2.2b.), is connected to the pressure regulator and myo-interface (Fig. 2.2c.). 
Briefly, the vessel segment was cannulated between the two glass cannulas each 
with diameter of ~ 100 i^m in a 10-ml chamber filled with Krebs solution (Fig. 2.2d.). 
The chamber solution was continuously bubbled with 95% 02-5% CO2 and maintained 
at 37 °C (pH 7.4), monitored by a built-in temperature probe (Fig. 2.2b.). One end of a 
ring segment was first secured on a cannula with two fine nylon sutures (Danish Myo 
Technology A/S, Denmark), the lumen was then flushed with Krebs solution at pressure 
difference less than 20 mmHg to clear any intraluminal blood. Another end of the 
segment was thereafter cannulated. Both cannulating pipettes were connected to 
independent Krebs-containing buffer bottles seated on a pressure regulator. The 
regulator controlled the flow rate and pressure applied to the segment mounted on the 
pressure myograph chamber. 
In no-flow condition, myogenic tone was allowed to develop fully before any 
experimental manoeuvre. A video camera attached to a light-inverted microscope 
(Zeiss Axiovert 40 Microscope, Model HOP) was used to visualize the segment of an 
artery, and data were recorded to disk. Outer diameters of the vessels and luminal 
pressure were measured continuously using the software Myo-View (version 1.1 P, 
2000，Photonics Engineering Ltd., Denmark). 
I 
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Fig. 2_1d. 
A four-channel Multi Myograph System (Danish Myo Technology A/S, Denmark) 
iC爐 
One channel 一 — ^ ^ ^ ^ ^ ^ ^ ^ 
Fig. 2.1 e. 
A Krebs-containing chamber of the Multi Myograph System with a vessel segment 
mounted with two tungsten wires. • = a vessel segment 
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Fig. 2.2a. 
A diagram of a Pressure Myograph C h a m b e r . 
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Fig. 2.2b. 
The chamber of a Pressure Myograph Setup (Danish Myo Technology A/S, 
Denmark), with Krebs solution being continuously bubbled with 9 5 % 02-5% CO2, 
is placed on the stage of a light-inverted microscope. 
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Fig. 2.2c. 
i 
A schematic diagram showing connections between the Pressure Myograph 
Chamber, Pressure Regulator and Myo-lnterface. 
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Fig. 2.2d. 
Cannulation of a rat small mesenteric artery between the two glass cannulas. 
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2.3. Intracellular [Ca^^] Measurement in Vascular Smooth Muscle 
Experimental protocols for intracellular Ca^^ measurement in 
pulmonary arteries are described in Methods and Materials section of Chapter 3. 
2.4. Chronic Raloxifene Therapy in Spontaneously Hypertensive Rats 
(SHRs) and Wistar-Kyoto (WKY) Rats 
2.4.1. Surgical Procedure - Raloxifene Tubing Insertion 
Three-month old male SHRs (weighing � 3 4 0 - 400 g) and WKYs (weighing � 
370 - 430 g) were supplied by the Laboratory Animal Services Center, the Chinese 
University of Hong Kong. SHRs or WKYs were divided into 2 groups (control and 
raloxifene treatment group). The raloxifene treatment group received oral 
administration of raloxifene (2.5 mg/kg/day) via gastric gavage for 15 weeks. All rats 
were maintained under the controlled conditions of humidity (47 - 48 %), temperature 
(20 °C) and light (12 hours of light, 12 hours of dark). They had free access to drinking 
water and rat chow. After 15 weeks, the rats were euthanized and desired arteries were 
collected (Fig. 2.4a.). 
2.4.2. Body Weight, Mean Arterial Blood Pressure and Uterine Weight 
Mean arterial blood pressures were measured by using a tail-cuff method. Body 
weights were measured, while the uteri were carefully isolated and weighed at the time 
of sacrifice. 
\ 
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2.4.3. Measurement of Raloxifene Tubing Consumption 
Before tubing insertion, the initial weight of the raloxifene-filled tubing was 
measured. At the time of sacrifice, the inserted tubing was taken out, dried overnight 
with an oven, and then weighed. 
By subtracting the final weight of the tubing from the initial value, the amount 
of raloxifene consumed in grams was obtained. 
2.4.4. Effect of Chronic Raloxifene Treatment on Artery Reactivity 
Experimental protocols for isometric tension measurement in pulmonary arteries 
are described in Methods and Materials section of Chapter 4. 
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The illustration showing chronic raloxifene treatment of rats. S H R s control; 
S H R s + raloxifene; W K Y s control; and W K Y s + raloxifene. ’ 
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2.5. Ovariectomy and Chronic Raloxifene Therapy in Syrian Golden 
Hamsters 
2.5.1. Surgical Procedure 一 Ovariectomy (OVX) 
Old female Syrian golden hamsters (〜12-month old, weighed about 120 - 200 g) 
were supplied by the Laboratory Animal Services Center, the Chinese University of 
H o n g K o n g . They were divided into 4 groups (Fig. 2.5a.). T w o of the groups were 
anaesthetized with 3 m l of a mix of ketamine and xylaxine (1.5 to 1, v/v) per kg body 
weight. Bilateral ovariectomy ( O V X ) was done aseptically via a mid-abdominal route. 
T w o weeks after O V X , the ovariectomized hamsters were randomly divided into 2 
groups ( O V X and O V X + raloxifene) and allowed free access to high-cholesterol ( H C ) 
diet and drinking water. 
2.5.2. Surgical Procedure - Raloxifene-filled Tubing Insertion 
T w o weeks after O V X , the ovariectomized hamsters were anaesthetized with 3 
m l of a m i x of ketamine and xylaxine (1.5 to 1，v/v) per kg body weight inserted 
subcutaneously with a raloxifene powder-filled Silastic® tubing ( D o w C o m i n g ) in the 
back. After insertion, they were placed in separate cages and given free access to H C 
food and drinking water for 3 months (Fig. 2.5b.). All hamsters were maintained under 
a controlled condition of humidity (47 - 48 % ) , temperature (20。C) and light (12 hours 
of light, 12 hours of dark). 
2.5.3. High-Cholesterol (HC) Food Preparation 
The H C diet consumed by hamsters was prepared using different proportions of 
the following ingredients: casein, lard, starch, sucrose, mineral mix, vitamin mix, D L -
methionine, pure cholesterol, dietary fibre, and gelatin. In the diet, 0.1 % pure 
cholesterol and a 4-fold of lard were added (detailed in section 2.6.3., table 2.6c.). 
Gelatin solution (20 g/L), in a ratio of 1 kg diet per litre of solution, was used to m i x all 
i 
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the powdered diets. Once the gelatin had set, the diet was cut into approximately 10 g 
cubic portions and stored at -20 to keep fresh before use. 
2.5.4. Body Weight, Food Consumption and Uterine Weight 
B o d y weights of hamsters were measured once a week. Food consumption was 
measured twice a week. W e t weights of uteri were measured at the time of sacrifice. 
2.5.5. Measurement of Raloxifene Tubing Consumption 
Before tubing insertion, the initial weight of the raloxifene-filled tubing was 
measured. At the time of sacrifice, the inserted tubing was taken out, dried overnight 
with an oven, and then weighed. 
B y subtracting the final weight of the tubing from the initial value, the amount 
of raloxifene released in grams was obtained. The average amount of raloxifene 
released in a kg body weight of a hamster per day was 0.0986 )j.g/kg/day. 
2.5.6. Serum Lipid and Lipoprotein Determinations 
Serum triglycerides (TG) and total cholesterol (TC) levels were determined by 
using enzymatic kits (Sigma Chemical, St. Louis, M O , U S A ) . High-density lipoprotein 
cholesterol ( H D L - C ) was measured after precipitation of low-density lipoprotein ( L D L ) 
and very low-density lipoprotein ( V L D L ) with phosphotungstic acid and magnesium 
chloride, using a commercial kit (Sigma). 
2.5.7. Effect of Chronic Raloxifene on Artery Reactivity 
Experimental protocols for isobaric diameter measurement in septal coronary 
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2.6. Solutions and Drugs 
2.6.1. Drugs, Chemicals and Enzymes 
Table 2.6a. contains a list of chemicals, drugs and enzymes used in this study. They 
were purchased from Sigma (Sigma Chemicals, St. Louis, M O , U S A ) , Tocris (Tocris 
Cookson Ltd., U K ) , Invitrogen (Life Technologies, U S A ) , Molecular Probes (Molecular 
Probes Inc., Eugene, Oregon, U S A ) or Eli Lilly & C o m p a n y (Lilly Corporate Center, 
Indianapolis, IN, U S A ) . The chemical safety for using these compounds was approved 
by the Safety Office, the Chinese University of H o n g K o n g , H o n g Kong. 
Table 2.6a. Chemicals, drugs and enzymes 
Chemicals Description Solvent Source 
1 4 0 0 W dihydrochloride Potent, highly selective i N O S H 2 O Tocris 
inhibitor 
Acetylcholine hydrochloride Muscarinic receptor agonist; H 2 O Sigma 
( A C h ) Endothelium-dependent 
vasodilator 
4-aminopyridine (4-AP) K v channel blocker D M S O Sigma 
A p a m i n (Apa) SKca channel blocker H 2 O Sigma 
Charybdotoxin ( C T X ) Ky and B K c a channel blocker H 2 O Sigma 
Cycloheximide Protein synthesis inhibitor D M S O Sigma 
9 , l l-Dideoxy - l l a , 9 a Thromboxane A2 analogue, D M S O Sigma 
-epoxymethano-prostaglandin vasoconstrictor 
F2a(U46619) 
Dimethyl sulphoxide ( D M S O ) Organic solvent for drugs -- Sigma 
Ethyleneglycotetraacetic acid Ca抖 chelating agent H 2 O Invitrogen C o . 
( E G T A ) -
17p-estradiol Female steroid hormone D M S O Sigma 
Fura-2 A M Ca"^ indicator/dye D M S O Molecular 
Probes Inc. 
I 
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Iberiotoxin (IBX) Specific BKca channel blocker H 2 O Sigma 
ICI 182,780 Estrogen receptor antagonist D M S O Tocris 
Indomethacin Cyclooxygenase inhibitor D M S O Sigma 
L-Arginine Nitric oxide precursor H 2 O Sigma 
L Y 294002 hydrochloride Selective phosphatidylinositol D M S O Tocris 
3-kinase (PI3K) inhibitor 
Nifedipine L-type V G C C blocker D M S O Sigma 
N^-nitro-L-arginine methyl Non-specific nitric oxide H 2 O Sigma 
ester ( L - N A M E ) synthase inhibitor 
lH-[l,2,4]oxadizolo[4,3-a] Guanylate cyclase inhibitor D M S O Sigma 
quinoxalin-l-one ( O D Q ) 
Phenylephrine H C l (Phe) ai-Adrenoceptor agonist H 2 O Sigma 
Pluronic F-127 2 0 % solution For prevention of Fura-2 D M S O Molecular 
secretion Probes Inc. 
Raloxifene H C l Selective estrogen receptor D M S O Eli Lilly & Co. 
modulator 
Sodium nitroprusside (SNP) Exogenous nitric oxide donor H 2 O Sigma 
Tamoxifen citrate (Tarn) Selective estrogen receptor D M S O Sigma 
modulator 
Tetraethylammonium chloride Non-selective K + channel H 2 O Sigma 
(TEA+) blocker 
Wortmannin Potent, irreversible inhibitor of D M S O Tocris 
PI3K 
The stock solutions of drugs were prepared and stored in distilled water or D M S O and 
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2.6.2. Solutions 
Table 2.6b. Composition of modiHed Krebs-Henseleit solutions 
Chemicals iKrebs- ICa^^-free |60 mM K+ ICa^^-free 
Henseleit Krebs- (mM) 60 mM K+ 
(mM) Henseleit (mM) (mM) 
SZI TI9 TT9 « ^ 
N a H C O s ^ S ^ ^ 
MgCl2.6H20 1 1 1 1 
m 4J 4J ^ ^ 
K H 2 P O 4 L 2 I 2 L 2 1.2 
CaCl2 ^ 0 0 
D-glucose T U T U T U T U 
The solutions were freshly prepared before the experiments. 
2.6.3. Diet Composition for Syrian Golden Hamsters 
Table 2.6c. Composition of HC diet for Syrian Golden Hamsters 
Ingredient HC Diet 
Casein ^ 
Lard 2 0 % 
Starch 38.6% 
Sucrose I W O 
Mineral M i x 4 % 
Vitamin M i x 2 % 
DL-Methionine 0 1 % 
Pure Cholesterol 0.1% 
~ Gelatin - 2 % 
^ Fibre ^ 
t S S 1 0 0 % 
H C diet = High-Cholesterol Diet 
( 
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2.7. Statistical Analysis 
Statistical significance was analyzed by two-tailed Student's t test for 
comparison of pECso, ^ D i and Emax, one-way analysis of variance ( A N O V A ) followed 
by student-Newman-Keuls test or two-way A N O V A followed by Bonferroni post-tests 
w h e n more than two groups were compared. A P value < 0.05 was considered as 
significant. All results were expressed as means 土 S.E.M. of n determinations. 
I 
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CHAPTER III 
Raloxifene Relaxes Rat Pulmonary Arteries and 
Veins: Roles of Gender, Endothelium, and 
Antagonism of Ca!. Influx 
3.1. Abstract 
Effects of raloxifene have been documented in the systemic circulation. However, 
its impact on the pulmonary circulation is unclear. The present study investigated the 
role of gender, endothelial modulation and Ca^^ channel in relaxations evoked by 
raloxifene in rat pulmonary arteries and veins. Vascular responses were studied on 
isolated pulmonary blood vessels mounted in a myograph and constricted by U46619. 
Constrictions to C a C b were studied in Ca^^-free, 60 m M K+ solution. Changes in the 
intracellular calcium ion concentration ([Ca^^JO in vascular smooth muscle were 
measured using a calcium fluorescence imaging method. Raloxifene was more 
effective in relaxing U46619-constricted pulmonary arteries from male than female rats. 
Raloxifene-induced relaxation was unaffected by ICI 182,780, inhibition of nitric oxide 
(NO) pathway, or removal of the endothelium. In arteries without endothelium, 
raloxifene attenuated CaCb-induced constriction and CaCb-stimulated increase in 
[Ca2+]i with similar potencies. Raloxifene caused endothelium-independent 
relaxations in pulmonary veins albeit to a lesser degree than in pulmonary arteries. 
The venous responses showed a gender difference as raloxifene was more potent in 
male veins. In summary, raloxifene relaxed rat pulmonary arteries and this effect did 
not involve the endothelium/NO or ICI 182,780-sensitive estrogen receptors. 
Raloxifene, like nifedipine, reduced both constriction and increase in response to 
C a C b in high K+ solution. Raloxifene also relaxed high K+-constricted pulmonary 
veins. Our data indicate that raloxifene acutely relaxes rat pulmonary blood vessels 
primarily via inhibition of Ca^^ influx through voltage-sensitive Ca^^ channels. Finally, 
raloxifene induced more relaxation in blood vessels isolated from male than female rats. 
I 
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3.2. Introduction 
In spite of the favorable effects of hormone replacement therapy (HRT) on 
established cardiovascular risk factors suggested in early observational studies, the 
findings from a recent H R T clinical trial have questioned its long-term safety (Rossouw 
et al,, 2002). Designer estrogen or selective estrogen receptor modulators (SERMs) 
have been developed to avoid the clinical disadvantages of H R T . Raloxifene, a 
2"^-generation S E R M with anti-estrogenic effects on breast and uterus, represents a 
promising alternative to H R T as it exerts estrogenic effects on key cardiovascular risk 
factors (Saitta et al,, 2001b). Besides, recent clinical studies support a cardioprotective 
effect of raloxifene in w o m e n at high coronary risk (Barrett-Connor et ai, 2002). 
Female rats exposed to chronic hypoxia exhibited less pulmonary arterial 
hypertension (Rabinovitch et al., 1981) and right ventricular hypertrophy (McMurtry et 
al” 1973) compared with age-matched male rats. Similar to the systemic circulation, a 
mechanism for estrogen modulation of pulmonary artery relaxation m a y be mediated by 
augmented nitric oxide (NO) function (Gonzales et al., 2001). 
M a n y studies have explored the mechanisms for S E R M modulation of vascular 
tone in both systemic arteries and veins (Figtree et al, 1999; Bracamonte et al,, 2002; 
丁sang et al., 2004a). Vasorelaxation to raloxifene in females is influenced by ovarian 
hormonal status (Bracamonte et al., 2002). T w o main mechanisms reported for the 
vascular action of S E R M s in systemic vascular tissues are up-regulation of endothelial 
N O production (Figtree et ai, 1999; Bracamonte et al., 2002) and inhibition of L-type 
voltage-sensitive Ca^^ channels (Tsang et al., 2004b). However, no studies have 
examined S E R M regulation of vasomotor activity in the pulmonary vascular circulation 
and its potential as a new drug in the treatment of pulmonary arterial hypertension. 
Therefore, w e investigated the vascular effects of raloxifene, the roles of endothelial 
modulation, estrogen receptors, and Ca^^ channel antagonism in isolated rat pulmonary 
arteries and veins，as well as gender differences in the action of raloxifene. 
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3.3. Methods and Materials 
3.3.1. Blood Vessel Preparation 
This study was approved by the Animal Research Ethics Committee of Chinese 
University of Hong Kong. This investigation conformed to the Guide for the Care and 
Use of Laboratory Animals published by the U S National Institute of Health (NIH 
Publication No.85-23, revised 1996). Both female and male Sprague-Dawley rats 
weighing 250 - 300 g were euthanized. The lungs were carefully dissected out and 
placed in ice-cold Krebs solution. Second-order intralobal pulmonary arteries (internal 
diameter:〜200 iim) and main pulmonary veins (internal diameter: ~ 490 |im) were 
dissected free from lungs and the surrounding connective tissue was cleaned off under a 
dissecting microscope. Each blood vessel was cut into two ~ 1 - m m ring segments. 
Individual ring was mounted between 2 tungsten wires (40 |im in diameter) for 
measurement of isometric tension in a 5-ml organ chamber filled with Krebs solution. 
Each wire was fixed to the mounting jaws of the myograph (Danish M y o Technology 
A/S, Denmark). The chamber solution was continuously bubbled with 9 5 % 02-5% 
CO2 at 37 °C (pH 7.4). All rings were placed under an optimal resting tension 
(approximately 1 m N ) , which was the minimum level of stretch giving the largest force 
development in 60 m M K+ solution as determined on the length-tension relationship 
(Nyhan et al, 2002). In most experiments, the endothelial layer was mechanically 
removed by gently rubbing the luminal surface with a tungsten wire and the functional 
removal was verified by the lack of relaxation to 3 \xM acetylcholine. 
3.3.2. Protocols 
Thirty minutes after mounting, rings were first constricted by 100 n M U46619 and 
subsequently challenged with acetylcholine to confirm integrity or removal of the 
endothelium. They were then washed in Krebs solution to restore tension to baseline 
level and allowed to stabilize for 60 min. The role of endothelium/NO and estrogen 
receptors was first examined in pulmonary relaxant responses to raloxifene. For this 
series of experiments, rings were exposed for 30 min to each inhibitor (100 |iM 
( 
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N^-nitro-L-arginine methyl ester, 3 |iM 1 H-[ 1,2,4]oxadizolo[4,3-a]quinoxalin-1 -one, or 
10 )LIM ICI 182,780) before addition of U46619. Once steady blood vessel tone was 
obtained, raloxifene was applied cumulatively to the bathing solution. Only one 
concentration-response curve to raloxifene was obtained per ring in the presence of each 
inhibitor. The ability of raloxifene to modulate Ca^^ influx via L-type 
voltage-sensitive Ca^^ channels was studied on constrictions to CaCl2 in rings without 
endothelium. For this set of experiments, two consecutive concentration-dependent 
constrictions to C a C b were obtained in control and in the presence of raloxifene (0.1 -
10 ]xM, 30-min incubation) before repeating the second concentration-response curve. 
For constructing C a C b concentration-response curve, arterial rings were rinsed 3 times 
in a Ca2+-free solution containing 30 fiM Na2-EGTA, then incubated in Ca^ '^ -free, 60 
m M K+ solution prior to cumulative addition of C a C b (0.1 - 5 m M ) . The effect of 
nifedipine (1 |LIM) was tested as control. The relaxing effect of raloxifene was also 
studied on 60 m M K+-constricted rings in normal Ca2+-containing Krebs solution. W e 
finally examined the effect of raloxifene on isolated rat pulmonary veins and the role of 
the endothelium/NO. 
3.3.3. Measurement of Vascular Smooth Muscle [Ca^ +h 
[Ca2+]i was measured in Fura-2-loaded pulmonary artery smooth muscle using the 
ratio imaging. Rings were incubated for 1 hr at 22 °C in a Fura-2 loading solution that 
contained: 10 |jM Fura-2 A M and 0.025 % pluronic F-127 (to prevent Fura-2 secretion). 
Thereafter, extracellular Fura-2 A M was removed by repetitive washing in Krebs 
solution. Rings were then perfused for 20 min with Krebs solution at 2 ml/min (37 °C) 
to permit cleavage of intracellular Fura-2 A M into active Fura-2 by esterases. Because 
of the ‘ Fura-2 photosensitivity, precautions were taken to avoid extensive 
photobleaching. The excitation light was blocked by a shutter when no fluorescence 
measurement was performed. 
— The [Ca2+]丨 imaging setup was modified from that described by Huang et al. (2000). 
In brief, after Fura-2 loading, cut-open artery rings without endothelium were mounted 
onto a block of silicone elastomer with stainless steel wires and pins (Sylgard, WPI), 
( 
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which was then fixed into a base plate of a custom-made flow chamber. The base plate 
was covered with a gasket and cover glass (24 x 32 m m ; thickness: no. 1; 
Menzel-Glaser, Germany) and affixed by screws. There was a 1 - m m gap between the 
vessel and the cover glass to allow flow passage. This arrangement also allows free 
vessel movement in response to addition of vasoactive drugs. After mounting, the 
flow chamber was placed on an inverted microscope and perfused at 2 ml/min with 
Krebs solution at 37 °C using a six-channel perfusion pump (Watson Marlow Corp., 
USA). 
Fura 2-loaded arterial tissues were viewed through a Nikon C F Fluor 20x objective 
on an inverted Nikon Eclipse TE300 microscope. Fura-2 was excited using a 
collimated beam of light from a 75 W xenon arc lamp, which passed through a 
microscope photometer D-104 (Photon Technology International, NJ, U S A ) that altered 
wavelengths from 340 to 380 n m using an optical chopper OC-4000 (Photon 
Technology International). The emitted light at 510 n m was collected by a 
photomultipliertube. Data acquisition and analysis were performed using FELIX 1.21 
software (Photon Technology International). 
After mounting, the arterial tissues were allowed to recover for 30 min at 37 °C 
and then exposed for 30 min to a Ca^^-free, 60 m M K+ prefusion solution. 
Subsequently, they were perfused with 60 m M K+ containing C a C b (0.1 - 3 m M ) to 
construct the first concentration-response curve. Rings were rinsed first in Ca2+-free 
solution and then in Ca^^-free, 60 m M K+ solution to allow returning of the Ca^^ level to 
baseline and finally incubated for 30 min with 300 n M or 10 i^M raloxifene before 
repeating the second C a C b concentration-response curve. 
3.3.4. Drugs 
Acetylcholine [2-(acetyloxy)-A/^,MA^-trimethylethanaminium], U46619 
[9,11 -dideoxy-11 a,9a-epoxymethanoprostaglandin F2a], L - N A M E [N^-nitro-L-arginine 
methyl ester], O D Q [1 H-[ 1,2,4]oxadizolo[4,3-a]quinoxalin-1 -one], and nifedipine 
[l,4-dihydro-2,6-dimethyl-4(2-nitrophenyl)-3,5-pyridinedicarboxylic acid dimethyl 
I 
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ester] were purchased from Sigma. ICI 182,780 
[7a-[9-[(4,4,5,5，5,-pentafluoropentyl)sulfmyl]nonyl]-estm-l，3，5(10)-triene-3，17B-diol] 
was purchased from Tocris. Raloxifene 
[[6-hydroxy-2-(4-hydroxyphenyl)benzo[6]thiophen-3-yl][4-[2-piperidinoethoxy]phenyl] 
ketone hydrochloride] was a gift from Lilly Corporate Center (Indianapolis, IN, USA). 
U46619, raloxifene, and nifedipine were dissolved in D M S O and others in distilled 
water. Further dilution was made from stock solutions. Krebs solution contained (in 
m M ) : 119 NaCl, 4.7 KCl, 2.5 CaCb, 1 M g C b , 25 N a H C O j , 1.2 KH2PO4, and 11 
D-glucose. High K+ solution was prepared by replacing Na+ with an equimolar amount 
of K+ to retain constant ionic strength. 
3.3.5. Data Analysis 
Results are means 士 S.E.M. of rings from n rats. Increases in constrictive force 
were expressed as percentages of the maximal response obtained in the first 
concentration-dependent constriction to CaCb. Concentration-response curves were 
constructed based on responses to cumulative drug concentrations and analyzed by 
non-linear curve fitting using Graphpad software (Version 3.0). The negative 
logarithm of the dilator (or constrictor) concentration that caused half {pDj or pECso) of 
the maximal response (Emax) was obtained. For statistical analysis, two-tailed 
Student's t test or one-way analysis of variance followed by Newman-Keuls test was 
used when more than two groups were compared. Individual concentration-response 
curves were also compared using a two-way analysis of variance followed by a post hoc 
test. P < 0.05 was considered to be significant. 
3.4. Results 
3.4.1. Effects of Raloxifene on Pulmonary Arteries 
- U46619 constricted rat pulmonary arteries to a comparable degree in both genders 
(tension: 3.71 士 0.60 m N with endothelium and 3.73 士 0.36 m N without endothelium in 
female, P > 0.05; 3.13 士 0.51 m N with endothelium and 2.98 士 0.34 m N without 
I 
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endothelium in male, P > 0.05). Upon U46619 pre-constriction raloxifene caused 
relaxations of arteries with and without endothelium (pDi： 4.78 士 0.13 versus 5.13 土 
0.13，P > 0.05 in female, Fig. 3.1a. and 5.34 士 0.15 versus 5.53 士 0.08，P > 0.05 in male, 
Fig. 3.Id.). Neither L - N A M E ( N O synthase inhibitor) nor O D Q (guanylate cyclase 
inhibitor) affected relaxation to raloxifene in female (Fig. 3.1b.) and male (Fig. 3.1e.) 
arteries. Likewise, ICI 182,780 was without effect on arteries from both genders (Fig. 
3.1c. & f.). ICI 182,780 m a y act as a partial estrogen receptor agonist (Bracamonte et 
al, 2002), but this agent (0.1 - 50 _ did not affect U46619-induced constriction (data 
not shown). Vehicle ( D M S O ) did not influence U466l9-induced tone in arteries with 
and without endothelium (Fig. 3.1a. & d.). 
There was a gender difference in relaxations to raloxifene in U46619-constricted 
arteries (pD�：4.78 士 0.13 in female and 5.34 士 0.15 in male, P < 0.05, Fig. 3.2a.), but 
this difference was absent in 60 m M K+-constricted arteries (pZV. 5.61 士 0.07 in female 
and 5.70 土 0.09 in male, P > 0.05, Fig. 3.2b.). The relaxing potency of raloxifene was 
greater in arteries constricted by 60 m M K+ than U46619. 
3.4.2. Effect of Raloxifene on CaCh-induced Constriction in Pulmonary Arteries 
In Ca2+-free，60 m M K+ solution, C a C b induced constrictions of arteries without 
endothelium (pECso： 3.81 士 0.15 in female and 3.77 士 0.11 in male, P > 0.05). 
Raloxifene reduced CaCb-induced constrictions in a non-competitive manner with 
progressive suppression of the maximal constriction in both female (Fig. 3.3a.) and 
male (Fig. 3.3b.) arteries. In control experiments, nifedipine (1 |iM) abolished 
constrictions to C a C b . 
3.4.3. Effects of Raloxifene on Pulmonary Veins 
U46619 constricted pulmonary veins (tension: 0.96 士 0.12 m N in female and 1.06 
-土 0.23 m N in male, P > 0.05). In U46619-constricted veins from both genders, 
raloxifene caused small relaxations and this effect was similar in arteries with and 
without endothelium (Fig. 3.4a. & c.). L - N A M E did not modify this relaxation (Fig. 
< 
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3.4b. & d.). 60 m M K+ constricted pulmonary veins (tension: 0.77 土 0.12 m N in 
female and 0.87 士 0.13 m N in male, P > 0.05) and this constriction was reduced by 
raloxifene (Fig. 3.5b.). Gender-related differences were demonstrated in the venous 
responses to raloxifene with a greater relaxing effect on male than female veins 
constricted by either U46619 or 60 m M K+ (Fig. 3.5a. & b.) 
3.4.4. Effect of Raloxifene on CaCb-stimulated Increases in in Pulmonary 
Arteries 
The effect of raloxifene on was examined in rings without endothelium. 
C a C b induced [Ca〗.]! rise in Ca2+-free，60 m M K+ solution and the first and second 
concentration-dependent responses were similar. Changes in measured as the 
fluorescence ratio (F340/F380) before and after treatment with raloxifene (0.3 and 10 
|LIM) in female and male pulmonary arteries are summarized in Fig. 3.6. The 
cumulative addition of C a C b caused progressive rises in [Ca^^ji and raloxifene reduced 
[Ca2+]i increases. There was no gender difference in the effect of raloxifene (Fig. 3.6). 
In control experiments, nifedipine (1 ^ iM) abolished CaCb-induced rise in [Ca】.]丨. 
I 
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Fig. 3.1. Concentration-dependent relaxations to raloxifene in female (a) and male (d) 
rat pulmonary arteries with and without endothelium, in arteries with endothelium 
treated by 100 |JM L-NAME or 3 |JM ODQ (b and e) or by 10 |JM ICI 182,780 (c and f). 
Arteries were constricted by U46619 following 30-min incubation with each inhibitor. 
Results are means 土 S.E.M. of 7 -10 experiments. 
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Fig. 3.2. Relaxation to raloxifene in (a) U46619- or (b) 60 mM K+-constricted 
arteries with endothelium from both female and male rats. Results are means 土 
S.E.M. of 7 - 8 experiments. 
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Fig. 3.3. CaCl2-induced contraction in Ca^^-free, 60 mM K+ solution in the 
absence and presence of raloxifene (0.1 to 10 pM) in arteries without 
‘endothelium from female (a) and male (b) rats. Results are means 土 S.E.M. 
of 6 experiments. 
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Fig. 3.4. Effects of raloxifene on U46619-constricted pulmonary veins from (a) 
female and (c) male rats. Lack of effect of 100 |JM L-NAME on relaxation to 
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Fig. 3.5. Gender differences in relaxant responses to raloxifene in pulmonary 
veins constricted by (a) U46619 or (b) 60 mM K+. Results are means 土 S.E.M. 
of 7 - 8 experiments. Statistical difference is indicated between two curves 
(*** p < 0.001, two-way ANOVA). 
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Fig. 3.6. Concentration-dependent increases in Ca^VFura 2-AM fluorescence 
in response to CaCIa in a Ca^^-free, 60 mM K+-containing solution and inhibitory 
effects of raloxifene (30 min incubation time) on rings from female (a & b) and 
male (c & d) rats. All experiments were performed on pulmonary artery rings 
without endothelium that were first incubated with Fura 2-AM for 45 min and 
perfused with Ca^'"-free, 60 mM K+ solution for 15 min prior to perfusion of 60 
mM K+ solution supplemented with CaClz (0.1 - 3 mM). Changes in [Ca^ j^i 
were recorded as the ratio (F340/F380) of Fura-2 fluorescence at excitation 
wavelengths of 340 and 380 nm. Data are expressed in means 土 S.E.M. of 
rings from four separate animals. Statistical difference is indicated between 
two curves (* P < 0.05; ***.P < 0.001, two-way ANOVA). 
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3.5. Discussion 
The new findings from this study using isolated rat pulmonary arteries and veins 
are: (1) raloxifene-induced pulmonary vascular relaxation was independent of the 
presence of endothelium; (2) raloxifene-induced acute effect is unrelated to ICI 
182,780-sensitive estrogen receptors; (3) raloxifene reduced CaCb-induced constriction 
and Ca2+ influx through nifedipine-sensitive Ca^ "^  channels; and (4) there was a gender 
difference in vascular responses to raloxifene. Some of these observations parallel 
those made in previous studies on the systemic vessels (Figtree et al., 1999; Tsang et al, 
2004b). This study of the acute effects of raloxifene suggests that raloxifene may 
reduce pulmonary pressure by inhibiting the activity of voltage-sensitive Ca^^ channels 
in vascular smooth muscle cells. 
Raloxifene inhibited high K+-induced constrictions, indicating that raloxifene may 
act as a Ca^^ channel inhibitor to cause pulmonary vascular relaxation. Similar effects 
were reported in systemic arteries (Figtree et al., 1999; Tsang et al., 2004b). 
Raloxifene also reduced CaCb-induced constriction in high K+ solution with 
progressive reduction of the maximal response; this further suggested that raloxifene 
interferes with Ca^ "^  influx through voltage-sensitive Ca^^ channels in these blood 
vessels. Ca^^ influx is the linker in excitation-contraction coupling in vascular smooth 
muscle upon membrane depolarization or constrictor stimulation. Indeed, the calcium 
antagonistic action of raloxifene was proven by the demonstration that raloxifene 
inhibits Ca^ "^  influx via Ca^^ channels as revealed by imaging measurement in 
Fura 2-loaded pulmonary vascular tissues without endothelium. The potency was 
similar for raloxifene between relaxing CaCb-induced tension and inhibiting 
CaCb-stimulated rise. Like the L-type Ca^^ channel blocker nifedipine, 
raloxifene at 10 |iM almost abolished CaCb-induced increase in both vessel tone and 
[Ca2+]i. Besides, high K+-constricted arteries exhibited higher relaxing sensitivity to 
raloxifene than U46619-constricted arteries. These data indicate that inhibition of Ca^ "^  
entry via L-type Ca^^ channels is an important mechanism by which raloxifene causes 
pulmonary vascular relaxation. 
I 
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Endothelial dysfunction characterized by progressive loss of the relaxation to 
NO-dependent dilators contributes to the development of hypoxic pulmonary 
hypertension (Adnot et al., 1991; Berkenbosch et al., 2000). Acute treatment with 
estrogen or phytoestrogens restored endothelial function in pulmonary arteries isolated 
from chronically hypoxic rats (Karamsetty et al., 2001). In the systemic circulation, 
raloxifene rapidly relaxed mammalian arteries and veins partly by increasing N O 
(Figtree et al” 1999; Bracamonte et ai, 2002). However, the present study shows that 
raloxifene induced relaxation to the same extent in pulmonary arteries with and without 
endothelium. Inhibition of N O pathway did not affect the relaxation. Despite the 
enhanced N O function described in the systemic arteries from raloxifene-treated rats 
(Wassmann et al,, 2002), the present data make a positive role of endothelium/NO in the 
acute pulmonary relaxation to raloxifene unlikely. This conclusion agrees with the 
observation that estrogen attenuated pulmonary hypertension via an eNOS-independent 
mechanism (Resta et al., 2001). 
The contribution of estrogen receptors to vascular responses to estrogen or S E R M s 
remains controversial and undefined. ICI 182,780, a selective estrogen receptor 
antagonist inhibited the non-genomic effects of raloxifene on the endothelium (Figtree 
et al., 1999), but not on vascular smooth muscle (Figtree et al, 1999; 丁sang et ai, 
2004b). The present study shows that ICI 182,780 failed to influence 
raloxifene-induced pulmonary artery relaxation. ICI 182,780 had no effect on 
relaxation to raloxifene in porcine femoral veins (Bracamonte et al, 2002). Instead, 
ICI 182,780 m a y act as a partial estrogen receptor agonist in femoral veins by causing 
relaxation (Bracamonte et al.’ 2002). However, ICI 182,780 did not induce significant 
relaxation in pulmonary arteries from both genders in the present study. Taken 
together, like its effects on some arteries in the systemic circulation (Bracamonte et ai, 
2002; Tsang et al., 2004b), the acute relaxation caused by raloxifene in pulmonary 
arteries in vitro does not involve ICI 182,780-sensitive estrogen receptor stimulation. 
However, it is unclear how raloxifene may act on Ca^^ channels in vascular smooth 
muscle if its effect is not mediated by estrogen receptors. Estrogen was shown to 
activate Ca^^-activated K+ channels by a direct interaction with the (3-subunit of the 
channel protein (Valverde et al., 1999). It is yet to elucidate whether the Ca^^ channel 
t 
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could provide such an interactive site for raloxifene. It should be noted that the present 
data do not preclude the chronic action of raloxifene on vascular estrogen receptors, 
which could contribute to long-term effects of raloxifene in the pulmonary circulation. 
There is a gender difference in hypoxia-induced pulmonary hypertension 
(Rabinovitch et al,, 1981) and right ventricular hypertrophy (McMurtry et al., 1973), 
but it is unknown whether this difference is influenced by the direct vascular effects of 
sex hormones. The gender difference was observed in relaxation to raloxifene of 
pulmonary arteries constricted by the receptor-dependent constrictor U46619, but not by 
the receptor-independent constrictor K+. The relaxing potency was higher in male than 
female arteries. This sexual dimorphism in raloxifene relaxation is more significant in 
pulmonary veins regardless of the type of constrictors used. Finally, the present study 
shows that raloxifene was less effective in pulmonary veins than arteries although the 
mechanism underlying that discrepancy is unclear. 
3.6. Conclusion 
In conclusion, the present findings provide experimental evidence for a key 
mechanism by which raloxifene relaxes rat pulmonary vessels. Raloxifene acts 
primarily on vascular smooth muscle of pulmonary arteries by inhibiting Ca^^ entry via 
L-type Ca2+ channels. This action is acute, non-genomic and independent of a 
functional endothelium or ICI 182,780-sensitive estrogen receptors. Such calcium 
antagonistic action may make raloxifene a potentially useful agent in the pulmonary 
arterial hypertension like an oral Ca^ "^  channel blocker if this effect also occurs in vivo. 
Raloxifene is clinically used to treat menopausal women, but the present in vitro data 
show that raloxifene appears to be more effective in causing pulmonary vascular 
relaxation in male than female animals. However, it remains to be investigated 
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CHAPTER IV 
Raloxifene Modulates Pulmonary Vascular 
Reactivity in Spontaneously Hypertensive Rats 
4.1. Abstract 
M a n y studies have explored the mechanisms for selective estrogen receptor 
modulators' modulation of vascular tone in systemic arteries and veins. I have recently 
reported the acute effects of raloxifene in isolated rat pulmonary arteries and veins and 
identified a primary mechanism by which raloxifene relaxed pulmonary blood vessels, 
e.g., inhibition of Ca^^ influx through Ca^^ channels. In this published study, the 
endothelium or nitric oxide ( N O ) was not involved in the acute relaxation to raloxifene. 
However, it was completely unknown whether chronic raloxifene treatment could 
modulate endothelial function and vasomotor activity in pulmonary arteries in 
hypertension. The present study used normotensive Wistar-Kyoto ( W K Y ) rats and 
spontaneously hypertensive rats (SHR) receiving oral treatment with raloxifene. All 
rings were suspended in myograph and the changes in isometric tension were measured. 
Rings from W K Y rats contracted more to U46619 and acetylcholine than those from 
S H R rats and the difference was eliminated after chronic raloxifene treatment. Rings 
with endothelium contracted significantly more to U46619 after inhibition of N O 
synthesis pathway by L - N A M E (as an index of basal N O release) in control and 
raloxifene-treated S H R than control S H R rats. In the presence of L - N A M E , 
U46619-induced contraction was similar in rings from the 3 groups. U46619 induced 
less contraction after raloxifene treatment only in rings with endothelium from S H R rats 
and this effect was abolished upon mechanical removal of the endothelium. In W K Y 
rats, raloxifene treatment did not enhance the contribution of basal N O to 
U46619-induced contractions which were similar with and without raloxifene. 
Chronic raloxifene treatment did not modify endothelium-dependent relaxation to 
acetylcholine and endothelium-independent relaxations to sodium nitroprusside (SNP) 
or nifedipine even though the relaxation to acetylcholine or S N P was slightly impaired 
in rings from S H R rats. The reduced relaxation to S N P was normalized by raloxifene 
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treatment. Raloxifene treatment reduced CaCb-induced tone only in S H R but not in 
W K Y rats. The present results indicate that chronic treatment with raloxifene could 
improve pulmonary vascular function by (1) increasing basal N O release, (2) reducing 
vascular smooth muscle tone, and (3) improving the effect of N O on vascular smooth 
muscle in S H R rats. In contrast, raloxifene has little effect on vascular reactivity in 
pulmonary arteries from normotensive W K Y rats. 
4.2. Introduction 
Conventional hormone replacement therapy ( H R T ) incurred debate on its safety in 
preventing cardiovascular diseases (Riggs et al., 2003; Rossouw et al, 2002). H R T 
users had higher incidences of strokes, heart attacks, and thrombosis (Rossouw et al., 
2002) although the precise mechanism is unclear. T o avoid the clinical disadvantages 
of H R T while maintaining the estrogenic effects, designer estrogen or selective estrogen 
receptor modulators ( S E R M s ) retaining beneficial properties of estrogen on bone, lipids, 
and the cardiovascular system but with antiestrogenic activity on breast and uterus have 
been developed. In particular, raloxifene (LY 156758)，a 2"'^-generation S E R M 
exerting antiestrogenic effects on the breast and uterus, m a y be a promising alternative 
to H R T because it lowered the level of key cardiovascular risk factors (Saitta et al., 
2001b) while bringing the effects of estrogen. Raloxifene was shown in recent clinical 
studies to be cardioprotective on w o m e n at high coronary risk (Barrett-Connor et al., 
2002). 
Vascular actions of S E R M s on the systemic vascular circulation have been studied 
extensively in vitro (Figtree et al., 1999; Tsang et a!” 2004b) and in vivo (Bracamonte et 
a/., 2002; Tsang et al, 2004a). Increased endothelial N O production and release and 
inhibition of L-type voltage-sensitive Ca^^ channels are the two primary mechanisms 
for the acute vascular effects of S E R M s in the isolated systemic blood vessels (Figtree 
et al, 1999; Tsang et al, 2004b). Ovarian hormonal status affected vasorelaxation to 
raloxifene in female (Bracamonte et al.’ 2002). Raloxifene reduced systemic blood 
pressure and arterial stiffness in postmenopausal w o m e n (da Costa et aL, 2004). 
I 
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A s far as the pulmonary circulation is concerned, nothing is k n o w n about the 
chronic S E R M modulation of vasomotor reactivity although the acute effects of 
raloxifene have been recently described in the pulmonary vascular circulation (Chan et 
al., 2005). It acted primarily on vascular smooth muscle of pulmonary arteries by 
inhibiting Ca^^ entry via L-type Ca^^ channels. This action was acute, non-genomic, 
endothelium-independent and ICI 182,780-insensitive. The calcium antagonistic 
action m a y m a k e raloxifene potentially a useful agent in treating the pulmonary arterial 
hypertension like an oral Ca^^ channel blocker if the effect occurs in vivo (Chan et al” 
2005). Nevertheless, no studies have examined the chronic effects of raloxifene on the 
pulmonary vascular system. This study was carried out to examine whether chronic 
raloxifene treatment could improve endothelial NO-mediated pulmonary artery 
relaxation in the male normotensive Wistar-Kyoto rats ( W K Y ) and spontaneously 
hypertensive rats (SHR). Especially, the present study investigated whether chronic 
raloxifene treatment leads to (1) enhanced basal N O release, (2) increased 
acetylcholine-stimulated NO-dependent relaxation, (3) alteration of vascular smooth 
muscle sensitivity to N O , and (4) alternation of endothelium-independent relaxation. 
4.3. Methods and Materials 
4.3.1. Raloxifene Treatment 
Three-month-old male spontaneously hypertensive rats ( S H R ) and Wistar-Kyoto 
( W K Y ) rats weighing ~ 365 g were purchased from the C U H K Laboratory Animal 
Center and rats were divided into two groups (control and raloxifene-treated). The 
treatment group received oral administration of raloxifene (2.5 mg/kg/day) via gastric 
gavage for 15 weeks. Blood pressures were measured by a tail-cuff method. This 
study was approved by the C U H K Animal Research Ethics Committee. 
4.3.2. Blood Vessel Preparation 
Rats were sacrificed by cervical dislocation. The lungs were removed and 
placed in ice-cold Krebs solution. Second-order intralobal pulmonary arteries were 
I 
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isolated and cut into 2 ring segments (1.73 土 0.09 m m in length). Each ring was 
suspended between wires that were attached to force transducers in a Multi Myograph 
System (Danish M y o Technology A/S) for measurement of isometric tone. Vessels 
were incubated in 5-ml chambers filled with Krebs solution that was bubbled with 9 5 % 
02-5% C O 2 at 37 °C (pH 7.2 - 7.4.) and allowed to stabilize for 60 min at 1 - m N optimal 
resting tension. In some rings the endothelial layer was mechanically denuded. 
Functional removal of the endothelium was verified by lack of a relaxant response to 
acetylcholine (1 |iM). Each experiment was performed on rings prepared from 
different rats. 
The size of pulmonary artery rings was similar between the two groups of rats 
(length/diameter: 1.74 土 0.14 m m / 6 0 4 士 60 \xm in control and 1.71 土 0.11 m m / 6 4 9 土 43 
l^m in raloxifene-treated S H R , P > 0.05). 
4.3.3. Experimental Protocols 
After 60-min equilibration, acetylcholine was used to relax U46619-contracted 
rings with endothelium. The relaxant effect of sodium nitroprusside was also 
examined in rings without endothelium. In another group of experiments, two 
consecutive concentration-response curves ( C R C ) to U46619 in normal Krebs solution 
were obtained in rings with and without endothelium. After the first C R C , rings were 
exposed to 100 L - N A M E for 30 min before repeating the second C R C . The 
concentrations of L - N A M E used in this study abolished acetylcholine-induced 
pulmonary artery relaxation. Contractions were determined as percentages of Emax 
obtained in the first C R C . Effect of nifedipine was tested on contraction induced by 60 
m M K C l in endothelium-denuded rings. 
At the end of each experiment, the length and internal and external diameters were 
measured for each ring studied. 
4.3.4. Chemicals and Drugs 
I 
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Acetylcholine [2-(acetyloxy)-iV^,A^-trimethylethanaminium]， U46619 
[9，11 -dideoxy-11 a,9a-epoxymethanoprostaglandin ， L - N A M E 
[N -nitro-L-arginine methyl ester], nifedipine 
[l,4-dihydro-2,6-dimethyl-4(2-nitrophenyl)-3,5-pyridinedicarboxylic acid dimethyl 
ester], sodium nitroprusside (Sigma), and raloxifene 
[[6-hydroxy-2-(4-hydroxyphenyl)benzo[^]thiophen-3-yl][4-[2-piperidinoethoxy]phenyl 
]ketone hydrochloride] (Eli Lilly and C o m p a n y Limited England). Krebs solution 
contained (in m M ) : 119 NaCl, 4.7 KCl, 2.5 C a C b , 1 M g C b , 25 N a H C O s , 1.2 K H 2 P O 4 , 
and 11 D-glucose. A high K + solution was prepared by substituting N a C l with an 
equal amount of K C l ions in order to retain constant ionic strength. 
4.3.5. Data Analysis 
Results are means 土 S.E.M. of n artery rings from different rats. The relaxant 
effects were expressed as the percentage reduction in U46619-induced contraction. 
The pZ)2 was calculated as the negative logarithm of the dilator concentration reducing 
the m a x i m u m relaxation (Emax) by 50 % . In order to demonstrate the contribution of 
endothelial N O in U46619-induced tone, the second C R C (after inhibition of N O S ) was 
subtracted from the first C R C (control) at individual concentration point. The amount 
of L-NAME-sensitive tone was compared between 2 groups. U46619- or 
CaCb-induced contractions were expressed as active wall tension (dividing the absolute 
tension by twice of the vessel length, m N / m m ) and pECso or p D j was the negative 
logarithm of the constrictor or dilator concentration that produced half the m a x i m u m 
response .(Emax). Student's t-test (two-tailed) was used and C R C s were analyzed by 
two-way A N O V A followed by Bonferroni post-tests. P < 0.05 was considered 
significant. 
4.4. Results 
4.4.1. Blood Pressure 
In control S H R rats, blood pressure continued to increase from 189 土 4.5 m m H g 
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to 226 士 4.3 m m H g in 3 months (P < 0.001). Chronic treatment (3 months) with 
raloxifene inhibited the increases in blood pressure (200.4 士 7.2 m m H g before treatment 
and 193.5 士 4.5 m m H g after treatment, P > 0.05). In contrast, the blood pressure in 
W K Y rats was lowered than that in S H R rats, with little changes during the duration of 
3 months (from 167.4 士 6.9 m m H g to 167.5 土 9.0 m m H g , P > 0.05). Raloxifene 
treatment slightly but insignificantly reduced the blood pressure in W K Y rats (from 154 
士 4.6 m m H g to 147.2 士 6.0 m m H g , P > 0.05) (Fig. 4.1.). 
4.4.2. Vasocontraction in Spontaneously Hypertensive Rats 
U46619 caused similar contractile responses in two • consecutive 
concentration-dependent curves in rings from control and raloxifene-treated S H R rats. 
Treatment with L - N A M E (100 fiM) enhanced U46619-induced contractions in rings 
with endothelium from both groups (Fig. 4.2a.). Rings from raloxifene-treated rats 
(Fig. 4.2b.) exhibited a greater augmentation of the U46619-induced contraction after 
inhibition of N O S as compared with that from control S H R rats (Fig. 4.2a.). The 
concentration-response curves for U46619 in the absence and presence of L - N A M E 
were shown in Fig. 4.3. The area (Fig. 4.3b. > Fig. 4.3a.) between the two curves 
indicates the degree of contribution of basal N O to U46619-induced contraction. Fig. 
4.3c. shows that the L-NAME-sensitive tone was significantly higher in rings from 
raloxifene-treated than rings from control S H R rats. 
A n increased N O contribution to U46619-induced contraction in 
raloxifene-treated S H R rats was also demonstrated clearly by reductions in vascular 
tone (presented as active wall tension in m N / m m ) as compared to that obtained in 
control S H R rats (Fig. 4.4a.). The reduced contraction after chronic raloxifene 
treatment was eliminated by the treatment of rings with endothelium with 100 ^iM 
L ~ N A M E (Fig. 4.4b.) or by the removal of the endothelium (Fig. 4.4c.). 
V, 
4.4.3. Vasorelaxation in Spontaneously Hypertensive Rats 
The endothelium-dependent relaxations to acetylcholine were compared in rings 
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from both groups of rats. Fig. 4.5a. shows that acetylcholine-induced vascular 
response consisted of two phases: initial relaxation at concentrations less than 10 
followed by concentration-dependent contraction in concentrations between 10 jiM and 
1 m M . R e m o v a l of the endothelium abolished both relaxing and constricting 
responses (n = 4，data not shown). This pattern of the vascular responses to 
acetylcholine was identical in rings from control and raloxifene-treated S H R rats (Fig. 
4.5a.). 
Likewise, sodium nitroprusside (SNP, a N O donor) caused 
concentration-dependent relaxations in rings without endothelium, which were similar 
in both sensitivity and maximal response for control and raloxifene-treated rats (pDj： 
7.77 土 0.05 in control and 7.98 土 0.06 in raloxifene treatment, P > 0.05，Fig. 4.5b.). 
SNP-induced relaxation was abolished in the presence of 3 [xM O D Q (an inhibitor of 
guanylate cyclase, n = 3, data not shown). 
In 60 m M KCl-contracted rings without endothelium, nifedipine caused 
relaxation with a p D i of 7.72 ±0.14 and Emax of 66.4 土 8.1 m N / m m in control S H R rats. 
Chronic raloxifene treatment did not affect the relaxation to nifedipine (p/)2： 7.72 土 0.06 
and Emax of 71.7 土 3.8 m N / m m , Fig. 4.6a.). In 60 m M KCl-containing, Ca^^-free 
solution, cumulative addition of CaCl2 induced concentration-dependent contraction in 
rings without endothelium and this contraction was significantly higher in rings from 
control S H R rats than rings from raloxifene-treated S H R rats (P < 0.05 between the two 
curves, Fig. 4.6b.). 
4.4.4. Vasocontraction in Wistar-Kyoto rats 
U 4 6 6 1 9 caused similar contractile responses in two consecutive 
concentration-dependent curves in rings from control and raloxifene-treated W K Y s . 
Treatment with L - N A M E (100 |LIM) enhanced U46619-induced contractions in rings 
with endothelium in both groups of rats (Fig. 4.7.). L - N A M E had similar effect on 
U46619-induced contraction in rings from control (Fig. 4.7a.) and raloxifene-treated 
W K Y rats (Fig. 4.7b.). The L-NAME-sensitive tone was similar in rings from control 
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and raloxifene-treated W K Y rats except for contraction induced by 10 n M U46619 (Fig. 
4.7c.). 
The contractions to U46619 were similar when they were expressed as active 
tensions in the absence (Fig. 4.8a.) and presence of 100 \xM L - N A M E (Fig. 4.8b.), or in 
rings without the endothelium (Fig. 4.8c.) in control and raloxifene-treated W K Y rats. 
4.4.5. Vasorelaxation in Wistar-Kyoto rats 
Fig. 4.9a. shows that like in S H R s , acetylcholine-induced vascular responses 
comprise two components: initial relaxation at concentrations between 3 n M and 10 |j.M 
followed by contraction at concentrations between 10 )j,M and 1 m M . The vascular 
effects of acetylcholine depended on the presence of the endothelium (n = 4，data not 
shown). This pattern of the vascular responses to acetylcholine was identical in rings 
from control and raloxifene-treated W K Y rats (Fig. 4.9a.). 
Similarly, sodium nitroprusside produced relaxations in rings without 
endothelium, with the same sensitivity and maximal response for control and 
raloxifene-treated W K Y rats (pD:: 8.05 士 0.04 in control and 8.19 土 0.20 in raloxifene 
treatment, P > 0.05, Fig. 4.9b.). SNP-induced relaxation was also prevented by 3 |aM 
O D Q in W K Y rats (n = 3, data not shown). 
Fig. 4.10a. shows that nifedipine relaxed 60 m M KCl-contracted 
endothelium-removed rings in a concentration-dependent fashion with a pDj of 7.53 土 
0.09 and Emax of 79.0 土 7.4 m N / m m in control W K Y s . Chronic raloxifene treatment 
did not affect nifedipine-induced relaxations (pD�：7.65 士 0.14 and Emax of 75.4 士 3.5 
m N / m m , Fig. 4.10a.). In 60 m M KCl-containing, Ca^^-free solution, cumulative 
addition of CaCl: induced contractions in rings without endothelium, which were 
comparable in rings from control and raloxifene-treated W K Y rats {P > 0.05 between 
the two curves, Fig. 4.10b.). 
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4.4.6. Comparison of contraction between WKY and SHR rats 
Rings from S H R rats contracted significantly more in response to U46619 as 
compared those from W K Y (Fig, 4.11a.) and this difference was absent after chronic 
treatment with raloxifene (Fig. 4.11b., Table 4.1.). Likewise, after relaxation phase, 
rings with endothelium contracted after further increases in the acetylcholine 
concentration and this contraction was higher in S H R than W K Y rats (Fig. 4.11c.). 
Again, the enhanced contraction to acetylcholine (> 10 jiM) was abolished in 
raloxifene-treated rats between the 2 groups (Fig. 4.1 Id., Table 4.1.). In contrast, 
CaCl2-induced contractions in a high K C l solution were the same in rings from W K Y 
and S H R rats (Fig. 4.1 le.). Chronic treatment with raloxifene reduced contractions 
induced by C a C b mainly in S H R rats (Fig. 4.1 If., Table 4.1.). 
4.4.7. Comparison of relaxation between WKY and SHR rats 
The rings from W K Y rats showed higher sensitivity to acetylcholine in inducing 
relaxation as compared with those from S H R rats, but the maximal relaxation was the 
same (Fig. 4.12a., Table 4.2.). This difference in relaxing sensitivity was widened 
after chronic raloxifene treatment on the 2 groups of rats (Fig. 4.12b.). Rings without 
endothelium from S H R rats showed reduced relaxations in response to sodium 
nitroprusside, a N O donor (Fig. 4.12c.) and this difference was abolished following 
chronic treatment with raloxifene (Fig. 4.12d.). In contrast, there was no difference in 
either sensitivity or maximal relaxation in response to nifedipine in rings without 
endothelium between W K Y and S H R rats regardless the treatment with raloxifene (Fig. 
4.12e.&f., Table 4.2.). 
\ 
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Table 4.1. Contractions in Rat Pulmonary Arteries 
WKY SHR —WKY+Rf SHR + Rf ~ 
U46619 at 0.3 i_iM 
Contraction 0.78 ±0.12 1.28 ±0.11* 0.99 ±0.21 0.73 土 0.06 
( m N / m m ) (6) (5) (5) . (5) 
P = 0.0145 P = 0.2680 
A C h at 0.3 m M 
Contraction 24.6 土 1.6 60.3 土 4.5 ‘ 32.9 士 10.8 49.1 士 5.4 
(6) (8) (5) (7) 
P = 0.0001 P = 0.2641 
CaCh 
pECso 4.31 ±0.07 4.20 ±0.07 4.30 士 0.07 4.25 ± 0.05 
P = 0.295 P = 0.5771 
P 1.35 ±0.17 1.39 ±0.08 1.58 ±0.18 1.08±0.11* 
[max 
(6) (5) (5) (5) 
户 = 0 . 8 4 6 9 P = 0 . 0 4 5 2 
Results are m e a n 土 S.E.M. of n experiments indicated in brackets. Significant 
difference is indicated by * P < 0.05 between W K Y and S H R groups or between W K Y 
+ R f and S H R + R f groups. 
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Table 4.2. Relaxations in Rat Pulmonary Arteries 
WKY SHR WKY+Rf SHR + Rf 
~ ~ A C h (+ Endo) 
pD2 7.00 土 0.06 6.68 ±0.05* 7.18 ±0.12 6.67 ± 0.04* 
P = 0.0013 P = 0.0007 
Emax 69.1 ± 3 . 5 7 0 . 1 ±3.8 86.2 ± 5.3 I 76.0 ± 3.2 
(6) (8) (6) (8) 
？ = 0 . 8 5 4 8 ？ = 0 . 1 0 7 7 
SNP (- Endo) T 
pD2 8.05 ±0.04 7.77 ±0.05* 8.19 ±0.20 7.98 ± 0.06 
P = 0.0016 ？ = 0 3803 
Emax 94.8 ± 2 . 3 7 7 . 1 土 1.5* 90.7 土 3.0 I 80.6 ±2.7' 
(6) (5) (6) (5) 
P = 0 0002 P = 0 0365 
Nifedipine (- Endo) 
7.53 ±0.09 7.72 ±0.13 7.65 ±0.14 7.72 ± 0.06 
pi)2 P = 0.2412 P = 06795 
79.1 ± 7 . 4 6 6 . 4 ±8.1 75.4 ± 3 . 5 | 71.7 ±3.8 
E 匪 (Z) Q (5) S  
P = 0.280 P = 0.494 
Results are m e a n 土 S.E.M. of n experiments indicated in brackets. Significant 
difference is indicated by P < 0.05 between W K Y and S H R groups or between W K Y 
+ R f a n d S H R + R f groups. 
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• S H R • W K Y 
_ S H R + Rf _ W K Y + R f 
”妄 250| 
i i n 
i § 200- I _ 
� o j U l l i U l l ^ 
90.0 
Treatment (day) 
Fig. 4.1. Measurements of systolic blood pressure by tail-cuff method of control 
W K Y and S H R rats or raloxifene-treated W K Y and S H R rats at day 0 and 90. 
Data are m e a n 土 S.E.M. of 9 rats in each group. 
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1 m N 
b 〜 … 〜 30 min 
SHR + Rf J 
—,.• II1 -.‘‘厂• I �I - ^ II 
r ^ • • 
U46619 L-NAME 100 I^ M 
(3，10’ 30 ,100, 300 n M )  
U46619 
(3, 10, 30,100, 300 n M ) 
Fig. 4.2. Representative traces showing two consecutive 
concentration-dependent contractions to U46619 in the absence and presence 
of L - N A M E in intralobal pulmonary artery rings with endothelium. 
Concentration-dependent contractions to U46619 obtained in rings from (a) 
control S H R and (b) raloxifene-treated S H R in the absence and presence of 
L - N A M E . Rings were exposed to 100 i^M L - N A M E for 30 min before 
repeating the second concentration-dependent responses. Scale bars apply 
to all traces. 
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a 
o 2 0 0 i。 Control 
I Q • L-NAME 
| i。。： 
- oJ SHR 
—I -nr 1 1 
-9 -8 -7 -6 
b U46619 (log M ) 
g 200-1 o Control 
I Q • L-NAME ___J 
II 
• � � • : 
oJ SHR + Rf 
I T 1 1 
-9 -8 -7 -6 
U46619 (log M ) 
� 
I 150-1 一 SHR 
' I § • ---SHR + Rf T 
• 1。0: / k K 
I 8 50- V 
」 0] 
—1 1 1 1 
-9 -8 -7 -6 
U46619 (log M ) 
Fig. 4.3. Concentration-response curves for U46619-induced contraction in 
rings from (a) control and (b) raloxifene-treated S H R (Rf) rats in the absence 
(O) and presence (•) of L - N A M E . Rings were exposed to L - N A M E for 30 
min before repeating the second concentration-response curve. (c) 
L-NAME-sensitive component of U46619-induced contractions w a s 
'determined by subtracting the first (control, without L - N A M E ) from the second 
(with L - N A M E ) concentration-response curve at each data point. Statistical 
difference between curves is indicated (*** P < 0.001，two-way A N OVA). 
Data are m e a n 土 S.E.M. of 6 rats in each group. 
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I I ！ ： 0 ： 产 
1 0.5-
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-9 -8 -7 -6 
U46619 (log M ) 
Fig. 4.4. U46619-induced contraction expressed as m N per milligram of 
length in millimeter of ring segments. Results were obtained in rings with 
endothelium prepared from control and raloxifene-treated S H R in the absence 
(a) and presence (b) of 100 L - N A M E . (c) U46619-induced contraction in 
'rings without endothelium from control and raloxifene-treated S H R . 
Statistical difference between curves is indicated (*** P < 0.001, two-way 
A N OVA). Data are m e a n ± S.E.M. of 6 rats. 
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a b 
I 1 0 0 j +Endo I 1 0 0 H . -Endo 
I 50- \ / 1 50-
i • — S H R i • o SHR ^ ^ 
〇」一SHR + Rf 〇」• SHR + Rf 
I 1 1 1 1 1 r I 1 1 1 r-
-9 -8 -7 -6 -5 -4 -3 - 1 0 -9 -8 -7 -6 
ACh (log M) SNP (log M) 
Fig. 4.5. (a) Concentration-relaxation curves for acetylcholine in 
U46619-contracted rings with endothelium and (b) concentration-relaxation 
curves for sodium nitroprusside (SNP) in rings without endothelium. These 
experiments were performed on rings prepared from control and 
raloxifene-treated S H R . Data are m e a n 土 S.E.M. of 5 - 6 rats. 
I 
CHAPTER III - ACUTE RALOXIFENE EFFECT IN PULMONARY A R T E R Y / 53 
a 〔 b 
1-5lo SHR ^ 
• r i ^ ^ - E n d 。 ！ “ 。 一 肩 *** 
I I P � _ 5 . X 
承 ° SHR < J r � 
一 0 � • SHR + Rf 0 . 0 � Z -Endo 
I 1 1 1 1~ 
- T o ~ ~ 5 5 ^ 5 -6 -5 -4 -3 -2 
Nifedipine (log M) CaCI? (log M) 
Fig. 4.6. (a) Concentration-relaxation curves for nifedipine in rings without 
endothelium, (b) CaCb-induced contraction expressed as m N per milligram 
of length in millimeter of rings without endothelium. These experiments were 
performed on rings prepared from control and raloxifene-treated S H R . 
Statistical difference between curves is indicated (*** P < 0.001, two-way 
A N O V A ) . Data are m e a n 土 S.E.M. of 5 - 6 rats. 
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。 C o n t r o l 
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5 J 1 0 0 - / y 
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C U46619 (log M ) 
•I 200-1 -^WKY 
1 . 一 WKY+Rf 
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Fig. 4.7. Concentration-response curves for U46619-induced contraction in 
rings from (a) control and (b) raloxifene-treated W K Y (Rf) rats in the absence 
(〇）and presence (•) of L - N A M E . Rings were exposed to L - N A M E for 30 
min before repeating the second concentration-response curve. (c) 
L-NAME-sensitive component of U46619-induced contractions w a s 
.determined by subtracting the first (control, without L - N A M E ) from the second 
(with L - N A M E ) concentration-response curve at each data point. Statistical 
difference between curves is indicated (*** P < 0.001, two-way A N OVA). 
Data are m e a n 土 S.E.M. of 6 rats in each group. 
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Fig. 4.8. U46619-induced contraction expressed as m N per milligram of 
length 
in millimeter of ring segments. Results were obtained in rings with 
endothelium prepared from control and raloxifene-treated W K Y in the 
.absence (a) and presence (b) of 100 ^iM L - N A M E . (c) U46619-induced 
contraction in rings without endothelium from control and raloxifene-treated 
W K Y . Data are m e a n 土 S.E.M. of 6 rats. 
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a b 
| l O O j 、 +Endo | l O O j 、 .Endo 圓 50_ 1 50-
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Fig. 4.9. (a) Concentration-relaxation curves for acetylcholine in 
U46619-contracted rings with endothelium and (b) concentration-relaxation 
curves for sodium nitroprusside (SNP) in rings without endothelium. These 
experiments were performed on rings prepared from control and 
raloxifene-treated W K Y . Data are m e a n 土 S.E.M. of 5 - 6 rats. 
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Fig. 4.10. (a) Concentration-relaxation curves for nifedipine in rings without 
endothelium, (b) CaCb-induced contraction expressed as m N per milligram 
of length 
in millimeter of rings without endothelium. These experiments were 
performed on rings prepared from control and raloxifene-treated W K Y . Data 
are m e a n 土 S.E.M. of 5 - 6 rats. 
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Fig. 4.11. Comparison of contractions in pulmonary arteries between W K Y 
and S H R rats (a, c & e) and between raloxifene-treated W K Y and S H R rats (b, 
d & f). Contractions to U46619 (a & b)，to acetylcholine (ACh, c & d) in rings 
-with endothelium and to CaCl2 in rings without endothelium (e & f). Data are 
m e a n 土 S.E.M. of 5 - 8 rats. Statistical difference between two curves is 
indicated by (* P < 0.05). 
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Fig. 4.12. Comparison of relaxations in pulmonary arteries between W K Y and 
S H R rats (a, c & e) and between raloxifene-treated W K Y and S H R rats (b, d & 
p. Relaxations to acetylcholine (ACh, a & b) in rings with endothelium, to 
sodium nitroprusside (SNP, c & d) and to nifedipine (e & f) in rings without 
endothelium. Data are mean 土 S.E.M. of 5 - 8 rats. Statistical difference 
between two curves is indicated by (* P < 0.05). 
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4.5. Discussion 
The n e w findings from the present investigation include (1) chronic raloxifene 
treatment enhanced the contribution of basal release of endothelial N O to 
receptor-dependent constrictors primarily in S H R rats with little effects on W K Y rats; (2) 
raloxifene treatment normalized the impaired relaxation to sodium nitroprusside in S H R 
rats as compared to W K Y rats; and (3) raloxifene treatment reduced contractile force 
induced by C a C b in rings from S H R rats with no effect on W K Y rats. The data 
indicate that raloxifene following chronic administration could improve endothelial 
function of rat pulmonary arteries in hypertension. 
The clinical importance of the endothelial N O pathway is well recognized. N O is 
protective against the development of atherosclerosis. Endothelial dysfunction, 
manifested as reduced N O levels, is one of the most c o m m o n pathological alterations in 
cardiovascular diseases and is characterized by impaired endothelium-dependent 
vasodilatation or by enhanced vasoconstriction (Vanhoutte, 1997). Raloxifene 
treatment augments flow-mediated vasodilatation in postmenopausal w o m e n probably 
through an increased N O production in the systemic circulation (Saitta et al., 2001a). 
Raloxifene therapy improves endothelial function by increasing the bioavailability of 
N O in spontaneously hypertensive rats (Wassmann et al., 2002). 
N O is derived from its precursor, L-arginine, and its synthesis can be prevented by 
L-arginine analogues, such as L - N A M E . Once released from the endothelial cells, N O 
readily diffuses towards the underlying vascular smooth muscle cells and stimulates the 
cyclic GMP-dependent pathway leading to relaxation that is sensitive to O D Q (an 
inhibitor of soluble guanylate cyclase). In the present study, differences in basal N O 
release can be determined indirectly as differences in the contractile responses to 
U 4 6 6 1 9 before and after treatment with L - N A M E . The present results show that 
pulmonary artery rings from raloxifene-treated S H R rats exhibited a greater increase in 
U46619-induced contractions in the presence of L - N A M E as compared with the 
L-NAME-sensitive enhancement of the contraction in control S H R rats. Besides, the 
active wall tension induced by U46619 was higher in S H R rats compared with 
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raloxifene-treated S H R rats. Concentration-dependent contractions to U46619 in the 
presence of L - N A M E or in rings without endothelium were similar in both groups of 
rats. The data indicate that the basal release of N O is augmented significantly in 
raloxifene-treated S H R rats. The present results are consistent with those obtained in 
systemic arteries from younger female rats treated with raloxifene for a shorter period of 
time (3 weeks) (Rahimian et al” 2002). Finally, CaCb-induced contractions were not 
reduced by raloxifene treatment in S H R rats, suggesting that the contractile mechanism 
in vascular smooth muscle m a y have been modified during raloxifene treatment. 
Taken in conjunction, the present data demonstrate that chronic raloxifene therapy 
augments a basal release of N O in pulmonary arteries in S H R rats. However, the 
beneficial effect of raloxifene primarily occurs in rings from S H R rats but not from 
normotensive W K Y rats, implying that like in systemic blood vessels, raloxifene could 
attenuate endothelial dysfunction in hypertension in the pulmonary circulation. 
Acetylcholine induced initial relaxation followed by contraction as its 
concentration increased further and this biphasic response was dependent on the 
presence of endothelium. The acetylcholine-induced NO-mediated relaxation was 
slightly but significantly reduced in S H R rats as compared with W K Y rats. Chronic 
treatment with raloxifene did not affect acetylcholine-induced relaxation in both groups 
of rats, but the difference in relaxation between W K Y and S H R rats appears to be 
increased after raloxifene treatment (Fig. 4.12b.). Normal endothelium-dependent 
vascular tone regulation is maintained by a functional balance between 
endothelium-derived relaxing and constricting factors ( E D R F & E D C F ) (Vanhoutte 
2005). Acetylcholine contracts the rat aortas after inhibition of the N O pathway (Yang 
et al., 2003). However, raloxifene treatment did not significantly affect 
acetylcholine-induced contraction in W K Y and S H R rats even though contractions in 
S H R rats were greater than those obtained in W K Y rats. The current results indicate 
that raloxifene treatment improves endothelial function by increasing basal release of 
N O and that decreasing receptor-mediated E D C F release/function m a y not be an 
important contributor. 
A n improved contribution of the NO-pathway following raloxifene treatment m a y 
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involve either stimulation of e N O S activity or greater expression of the e N O S protein 
S H R rats. Chronic raloxifene treatment in younger ovariectomized rats increased 
e N O S m R N A levels (Rahimian et al., 2002) and prevented decreased e N O S activity 
(Pavo et al., 2000) in systemic arteries. However, the present study cannot measure 
the possible impact of chronic raloxifene therapy on e N O S protein expression since (1) 
the mass of pulmonary arteries was small for Western blot analysis and (2) smaller 
pulmonary arteries were difficult to isolate. 
The present results cannot rule out the possibility that the impaired endothelial 
function is accompanied by a reduced sensitivity of vascular smooth muscle to N O in 
hypertension since the relaxation to sodium nitroprusside was diminished in S H R rats 
(Fig. 4.12c.). Chronic raloxifene therapy tended to restore the sensitivity to the N O 
donor, suggesting an additional benefit of raloxifene in the vascular system. However, 
little is k n o w n about the influence of raloxifene on the activity of cyclic GMP/protein 
kinase G-dependent pathways. 
In male S H R rats, chronic raloxifene treatment improved hypertension-induced 
endothelial dysfunction by increasing the bioavailability of N O and reduced vascular 
production of reactive oxygen species in aorta, causing a profound blood pressure 
reduction and lowered the degree of vascular damage (Wassmann et al., 2002). N O 
synthesis in systemic arteries from ovariectomized S H R s was restored after long-term 
treatment with raloxifene (Leitzbach et al, 2005). However, no studies have so far 
addressed the potential similar benefits in the pulmonary circulation. The present 
study is, probably the first one to examine the effects of chronic therapy with selective 
estrogen receptor modulator on vascular reactivity in pulmonary arteries in hypertension 
even though I have recently characterized the acute pharmacological action of 
raloxifene on both pulmonary arteries and veins in normotensive Sprague-Dawley rats 
(Chan et al.,2005). 
、Pulmonary vasoconstriction is believed to be an early event in the development of 
pulmonary arterial hypertension. Excessive vasoconstriction m a y be related to 
endothelial dysfunction and abnormal function of vascular smooth muscle (Humbert et 
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al., 2004). Endothelial dysfunction causes chronically impaired production of N O and 
prostacyclin and increases production and release of vasoconstrictors such as 
endothelin-1 and free radicals. Impaired endothelial function is supported by the 
demonstration of decreased expression of N O synthase in pulmonary artery endothelial 
cells from patients with pulmonary arterial hypertension (Giaid and Saleh, 1995). 
Current therapies for pulmonary arterial hypertension include anticoagulants, Ca^^ 
channel blockers, N O and endothelin receptor blockers (Archer and Rich, 2000). The 
recent demonstration of Ca^^ channel blocking effect of raloxifene in pulmonary arteries 
(Chan et aL, 2005) and findings from this study that raloxifene treatment improves 
endothelial function in pulmonary arteries in hypertensive rats, suggesting a potential 
vascular benefits in the pulmonary circulation under pathological conditions such as 
pulmonary arterial hypertension. It would be ideal to examine the effect of raloxifene 
on animal models of pulmonary arterial hypertension and this possibility will be 
explored in the future. Another regulator in controlling pulmonary vascular tone is the 
K + channel. Acute hypoxia appears to trigger hypoxic pulmonary vasoconstriction in 
part due to inhibition of voltage-gated K + (Ky) channels in pulmonary artery smooth 
muscle cells (Weir and Archer, 1995). Both loss of Kv channels and impaired Ky 
channel activity m a y occur in pulmonary arterial hypertension (Archer and Rich, 2000). 
Chronic treatment with tamoxifen, the 1'^-generation selective estrogen receptor 
modulator, was found to enhance m R N A expression of Ky channels in aortic smooth 
muscle cells from ovariectomized rats (Tsang et al., 2004c). If raloxifene therapy 
could increase expression and function of Kv channels to prevent membrane 
depolarization and opening of voltage-gated Ca^^ channels, this will be another vascular 
benefit of selective estrogen receptor modulators in pulmonary arteries. This 
likelihood warrants further examination. 
4.6. Conclusion 
- • 
In summary, the present study establishes that the basal N O release from 
endothelium-intact pulmonary artery is diminished in hypertensive rats and improved 
by chronic raloxifene treatment. This effect appears to occur mainly in S H R rats since 
raloxifene had little effect on either contraction or relaxation in normotensive W K Y rats 
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despite the exact reason for such a discrepancy is unclear. The results of this basic 
investigation indicate that raloxifene m a y be beneficial in combating pulmonary arterial 
hypertension. M o r e detailed studies are absolutely needed to demonstrate whether 
raloxifene could reduce hypoxia-induced acute vasoconstriction in pulmonary blood 
vessels and whether raloxifene therapy could improve endothelial function of the 
pulmonary circulation in chronically induced hypoxia before the results of basic 
research can be meaningfully related to the potential therapeutic value of raloxifene in 
clinical setting of pulmonary arterial hypertension. 
1 
CHAPTER V-RALOXIFENE EFFECT IN PRESSURIZED MESENTERIC ARTERY/ 100 
CHAPTER V 
Effects of Therapeutic Concentrations of 
Raloxifene in Pressurized Rat Small Mesenteric 
Artery 
5.1. Abstract 
Estrogen was found to reduce myogenic responses in mammalian resistance arteries. 
However, whether selective estrogen receptor modulators ( S E R M s ) could modulate 
vessel tone in resistance vessels is not studied. The present study investigated the role of 
endothelium and gender in vasodilatation evoked by raloxifene, a generation S E R M 
in rat myogenically active arteries. The effects on myogenic tone of the vessels were 
examined in isolated resistance mesenteric arteries that were cannulated in a pressure 
myograph chamber. 
Both raloxifene and 17p-estradiol at therapeutic or low concentration ranges 
produced concentration-dependent vasodilatations in myogenic tone-developed 
mesenteric arteries with endothelium from both genders. 17P-Estradiol was more 
effective than raloxifene in inducing vasodilatation. Arteries from female rats relaxed 
significantly more in response to raloxifene or 17p-estradiol than those from male rats. 
Raloxifene-induced vasodilatation in arteries with endothelium from female rats was 
attenuated by treatment with L - N A M E , an inhibitor of nitric oxide ( N O ) synthase. In 
contrast,'the dilatation was not affected by 1400W, an inhibitor of inducible N O synthase. 
17p-Estradiol-induced vasodilatation, however, was unchanged by treatment with 
L - N A M E in arteries with endothelium from female rats. Charybdotoxin ( C T X ) plus 
apamin did not influence raloxifene- or 17p-estradiol-induced vasodilatation in female 
rats. Raloxifene at 0.3 or 1' n M did not modulate acetylcholine (ACh)-induced dilatation 
that was markedly reduced by combined treatment with C T X plus apamin. ICI 182,780, a 
classic inhibitor of estrogen receptor, had no effect on vasodilatation induced by either 
raloxifene or 17(3-estradioL Wortmannin, LY294002 [both are inhibitors of 
I 
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phosphatidylinositol 3-kinase (PI3K)] and cycloheximide did not inhibit vasodilatation in 
response to raloxifene in female rats. 
In summary, this was the first study to demonstrate (1) that raloxifene in therapeutic 
concentrations (0.3 - 10 n M ) relaxed rat resistance mesenteric arteries which developed 
myogenic tone; (2) that raloxifene-induced vasodilatation appears to be mediated through 
a non-genomic mechanism, but involve L-NAME-sensitive endothelium-derived N O , 
while inhibition of inducible N O S was without effect; and (3) that the dilating effect of 
raloxifene exhibited a significant gender difference with being m u c h more potent and 
effective in female arteries than male arteries. 17p-Estradiol also dilated resistance 
arteries in a concentration-dependent fashion. The followings are the n e w findings 
regarding the vascular action of 17p-estradiol: (1) that 17p-estradiol-induced 
vasodilatation was inhibited by C T X plus apamin but not L - N A M E ; (2) that like 
raloxifene, 17p-estradiol produced greater vasodilating effect in female rings than male 
rings; and (3) that 17(3-estradiol-induced vasodilatation was insensitive to ICI 182,780. 
The results of the present investigation clearly demonstrate the vasodilator effects of both 
raloxifene and 17p-estradiol, but the endothelium-related mechanisms underlying both 
relaxations are different even though ICI 182,780-sensitive estrogen receptor is unlikely 
involved. The former is probably mediated through endothelial N O and the latter is 
mainly caused by C T X and apamin-sensitive hyperpolarizing factors in rat resistance 
arteries. Most importantly, therapeutic concentrations of raloxifene dilated resistance 
arteries mainly in female rats, indicating a significant target site of action for raloxifene in 
microcirculation. 
5.2. Introduction 
Myogenic response (or myogenic tone) refers to a spontaneous decrease in blood 
vessel diameter after increasing transmural pressure or an increase in vessel diameter 
after reducing pressure. Bayliss first described this vasomotor phenomenon in 1902 
(Bayliss, 1902). In response to neurohumoral stimuli, the myogenic response provides a 
basal tone for arterioles to adjust their internal diameters accordingly. This 
autoregulatory mechanism controls the basal peripheral vascular resistance and capillary 
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hydrostatic pressure (Johnson, 1981; Davis and Hill, 1999) to maintain a constant blood 
flow over a wide range of pressures under basal conditions. Such a mechanism is 
particularly crucial to maintain normal physiological function of the brain (cerebral 
circulation), heart (coronary circulation) and kidneys (renal circulation) (Johnson, 1989; 
Muller et al, 1996; Farad et al., 1989; R o m a n and Harder, 1993). 
17p-Estradiol was reported before to reduce myogenic responses in mammalian 
resistance arteries. Huang et al. in 1997 described a gender-related difference in 
pressure-induced diameter changes of gracilis muscle arterioles from male and female 
Wistar rats with a significant higher myogenic tone in male arterioles (Huang et aL, 
1997b). Ovariectomy enhanced the development of myogenic response in female rats 
and this alteration was normalized by chronic treatment with estrogen in ovariectomized 
( O V X ) rats (Huang et al., 1997a). Another study using Fisher 334 rat middle cerebral 
arteries also demonstrated a gender difference in the myogenic constriction (Geary et aL, 
1998). These results indicate that circulating estrogen levels influence the myogenic 
activity of arterioles in rats. It appears that circulating estrogen decreases myogenic tone 
indirectly by increasing the production of N O in endothelial cells since OVX-related 
augmentation in myogenic tone was less sensitive to N O S inhibition, which can be 
restored by chronic estrogen therapy (Geary et al, 2000). A more recent study using 
12-week-old C 5 7 Black mice middle cerebral artery (Geary et al, 2000) reported that 
inhibition of N O S significantly increased myogenic tone in arteries from male mice as 
compared with arteries from female mice. However, this gender difference was abolished 
following O V X and restored by estrogen replacement treatment (Geary et al, 2000). 
Although estrogen was shown to reduce myogenic response in a few studies, 
vascular tone modulation by S E R M s in resistance arteries is not examined. Most studies 
have so far used large, conduit arteries for characterization of pharmacological properties 
of S E R M s including raloxifene as well as estrogen under isometric conditions. It is 
possible that the sensitivity to dilators that are commonly used against hypertension m a y 
be significantly different w h e n vascular smooth muscle relaxation was measured under 
isometric and isobaric conditions as reported previously (Dunn et al, 1994). The 
myogenically active blood vessels are the major sites of resistance to blood flow in 
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several vital organs including the brain and heart and dilatation of these vessels has an 
important impact on local blood flow and oxygen supply. Therefore, the aim of the 
present study was to determine (1) whether raloxifene, a generation S E R M , in 
therapeutic concentrations could dilate resistance-sized mesenteric arteries and possible 
mechanisms involved; (2) whether there was gender difference in vascular response; and 
(3) what difference would be in vascular responses to raloxifene and 17p-estradiol. All 
experiments were performed on rat mesenteric arteries that possess the myogenic 
property. 
5.3. Methods and Materials 
5.3.1. Blood Vessel Preparation 
This study was approved by the Animal Experimentation Ethics Committee of the 
Chinese University of H o n g Kong. This investigation conformed to the Guide for the 
Care and Use of Laboratory Animals published by the U S National Institute of Health 
(NIH Publication N o . 85-23，revised 1996). Both female and male Sprague-Dawley rats 
weighing 250-280 g were euthanized by inhalation of C O 2 . The ileum and associated 
mesentery were quickly dissected out and immersed in ice-cold (4 °C) Krebs solution 
bubbled with a gas mixture of 9 5 % 02-5% CO2. The fourth-order mesenteric artery (〜 
2-3 m m long) with an outer diameter of 250-350 |am was carefully dissected free of 
surrounding adipose tissue under a dissection microscope. The artery was cut into several 
short ring segments and each segment was mounted on a Pressure Myograph System 
(Danish M y o Technology, Denmark) and changes in blood vessel diameter were 
measured. 
Briefly, each ring segment was cannulated between the two glass cannulas (each 
with tip diameter of -100 |im) in a chamber filled with 10-ml Krebs solution. The 
chamber solution was continuously oxygenated with 9 5 % 02-5% C O 2 and maintained at 
37 (pH 7.4) that was monitored by a built-in temperature probe. O n e end of the ring 
segment was first secured on a cannula with two fine nylon sutures (Danish M y o 
Technology, Denmark) and the luminal content including remaining blood was then 
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flushed through with Krebs solution using a perfusion device at pressure difference less 
than 20 m m H g . Another end of the segment was thereafter cannulated. Glass cannulas 
were pulled with a micropipette puller model P-87 (Shutter Instrument Company, Novate, 
CA). Both cannulating pipettes were connected to independent Krebs-containing buffer 
bottles seated on a pressure regulator. The pressure regulator controlled the flow rate and 
pressure applied to the ring segment that had been mounted on the pressure myograph 
chamber. A video camera attached to a light-inverted microscope (Zeiss Axiovert 40 
Microscope, M o d e l H O P ) was used to visualize the cannulated artery and changes in 
vessel diameters were recorded onto a computer hard drive. The outer diameter and 
luminal pressure were measured simultaneously using a software M y o - V i e w (version 1.1 
P, 2000, Photonics Engineering, Denmark). 
5.3.2. Experimental Protocols 
5.3.2.1. Myogenic Tone Development 
To develop myogenic tone in a no-flow condition, the artery segment was first 
subjected to step increment (every 20 m m H g , lasting for 3-5 min) in intraluminal pressure 
from 20 to 100 m m H g at room temperature (23 °C). After this procedure, the pressure 
was lowered and then maintained at 80 m m H g . Subsequently, the temperature of bathing 
solution started to increase gradually from 23 °C to 37 °C by switching on a heating 
device pre-installed in the pressure myograph chamber. This procedure normally took 
approximately 30 min. The chamber solution was maintained at 37 °C during the entire 
duration of the experiment. Under this condition, myogenic tone began to develop and 
arteries started to constrict as the vessel diameter decreased. After 30 to 60 minutes, the 
vessel diameter was stabilized and the myogenic response was fully developed. 
5.3.2.2. Effects of Raloxifene and 17p-EstradioI on Myogenic Constriction 
、After myogenic tone was stably developed in rat mesenteric arteries, raloxifene or 
17P-estradiol were added cumulatively (0.3 - 30 n M ) in approximate 30-min intervals 
between drug application to induce concentration-dependent vasodilatations. At the end 
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of each experiment, arteries were constricted by 1 |iM Phe and then dilated by 1 [xM A C h 
to confirm the presence of the endothelium. If arterial rings with endothelium could not 
relax over 8 0 % in response to 1 \xM A C h , they were discarded in the present study. 
Finally, the superfusate was replaced with a Ca^'^-free Krebs solution containing 2 m M 
E G T A to obtain the maximal passive vasodilatations which were used for data analysis 
and expression in an isobaric condition. 
5.3.2.3. Effects of Pharmacological Inhibitors on Raloxifene- or 
17(3-Estradiol-mduced Myogenic Constriction 
To study the role of endothelium-derived vasodilating factors, arterial rings after the 
development of myogenic constriction were incubated for 30 min with each of the 
following pharmacological inhibitors: L - N A M E (30 an inhibitor of N O S ) or C T X 
plus apamin (each in 50 n M , a recipe used to inhibit E D H F ) . Either raloxifene or 
17P-estradiol was subsequently added extraluminally to the bathing solution. The effects 
of ICI 182,780 (1 |iM, an inhibitor of classic estrogen receptor), 1 4 0 0 W (100 n M , an 
inhibitor of inducible N O S ) , wortmannin (50 n M , an inhibitor of PI3K), L Y 294002 (1 
|LIM，an inhibitor of PI3K) or cycloheximide (10 |iM, an inhibitor of protein synthesis) 
were also examined on vasodilatation induced by raloxifene in arterial rings with 
endothelium. After 30-min exposure to each of the above-mentioned inhibitor with stable 
myogenic tone, raloxifene was applied cumulatively. The time-matched control 
experiments were also performed to ensure that the vasodilating response was not caused 
by rapid decline in myogenic constriction in these arteries. 
5.3.3. Drugs and Solutions 
Acetylcholine, phenylephrine, N'^-nitro-L-arginine methyl ester ( L - N A M E ) , 
np-estradiol, apamin, charybdotoxin (CTX), nifedipine and cycloheximide were 
purchased from Sigma (St. Louis, M O , U S A ) . ICI 182,780, 1 4 0 0 W dihydrochloride, L Y 
V. 
294002 hydrochloride and wortmannin were purchased from Tocris. 
Ethyleneglycotetraacetic acid ( E G T A ) was purchased from Invitrogen Corporation 
(Carlsbad, California, U S A ) . Raloxifene was a gift from Eli Lilly Corporate Center 
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(Indianapolis, IN, U S A ) . 
Raloxifene, 17P-estradiol, cycloheximide, ICI 182,780, L Y 294002 hydrochloride, 
nifedipine and wortmannin were dissolved in D M S O (Sigma) and others in distilled water. 
Further dilution was made from stock solutions. Krebs solution contained (in m M ) : 119 
NaCl, 4.7 KCl, 2.5 C a C b , 1 M g C b , 25 N a H C O j , 1.2 K H 2 P O 4 , and 11 D-glucose (Refer to 
table 2.6b in section 2.6.2 of chapter 2). High K+ solution was prepared by replacing N a C l 
with an equimolar amount o f K C l in order to retain constant ionic strength. The Ca^^-free 
Krebs solution was identical to Krebs solution with the exclusion of Ca^^ and the addition 
of 2.0 m M E G T A . Bathing solution was continuously aerated with 9 5 % 02-5% C O 2 to 
maintain a constant p H value (7.4). 
5.3.4. Expression of Results and Statistical Analysis 
Percent Dilatation was calculated using the equation 1 0 0 % x [(Dd-Db)/(Dca-free-Db)], 
where D is the diameter on stabilization after drug addition (d), baseline (b) or Ca^^- free 
condition. The larger the percentage of dilatation, the smaller is the myogenic tone. 
The results are expressed as mean 土 S.E.M. of n rats. Each experiment was carried 
out on rings prepared from different rats. Student's t- two-tailed test or analysis of 
variance ( A N O V A ) was used for statistical evaluation w h e n more than two groups were 
compared. P values less than 0.05 were taken as statistically significant. 
5.4. Results 
The average outer diameter for female and male rat resistance mesenteric arteries 
under experiments were 361.30 士 4.31 and 353.40 ± 10.33 |j,m respectively. 
5.4.1. Effects of Raloxifene and 17p-Estradiol on Rat Resistance Mesenteric 
Arteries 
The representative trace in Fig. 5.1a. shows a ring segment from a female rat with 
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350 i^m outer diameter before development of myogenic tone. Shortly after maintaining 
the intraluminal pressure at 80 m m H g , the ring started to constrict. The myogenic 
constriction was normally stabilized within 30 min. Cumulative addition of raloxifene 
(0.3-30 n M ) caused vasodilatation with a maximal dilation at concentration between 10 
and 30 n M . The trace in Fig. 5.1b. shows that raloxifene was m u c h less effective in 
causing vasodilatation in a ring prepared from the male rat mesenteric artery. The p D i 
value (the concentration that causes 5 0 % maximal vasodilatation) for raloxifene-induced 
dilatation was 8.91 士 0.18 in female arteries and 8.15 ± 1.93 in male rings. The dilating 
effect induced by raloxifene at 3, 10 and 30 n M was different between the female and 
male arteries (P < 0.001, Fig. 5.1c.). 
Likewise, 17p-estradiol induced concentration-dependent vasodilatation in both 
genders (Fig. 5.3.). The dilating effect induced by 17p-estradiol at 0.3, 1 and 3 n M was 
different between the female and male arteries (P < 0.001, Fig. 5.3c.). But the maximal 
dilatation to 17p-estradiol was the same in female and male arteries (Fig. 5.3c.). It 
appears that 17P-estradiol was more effective than raloxifene in inducing dilatations in 
both genders (comparison between Fig. 5.2. and Fig. 5.3c.). Representative traces for the 
dilating effect of raloxifene, estrogen and time-matched control in male arteries with 
endothelium are shown in Fig. 5.14. There is a statistical difference (P < 0.01) between 
the concentration-response curves for dilatation induced by raloxifene and 17p-estradiol 
in male arteries with endothelium (Fig. 5.15.). 
5.4.2. Effects of Inhibitors of NOS 
In order to show whether endothelium-derived N O were involved in raloxifene- or 
17p-estradiol-induced vasodilatation, arteries were treated with 30 |j.M L - N A M E for 30 
min after stable myogenic constriction. Fig. 5.4b. shows a small constrictive response to 
the addition of L - N A M E in a female artery and L - N A M E reduced the dilating effect of 
raloxifene as compared with the response in the absence of L - N A M E (Fig. 5.5.). The 
percentage dilatation induced by raloxifene at 3 and 10 n M was significantly different 
with and without treatment with L - N A M E (Fig. 5.5.). The time-matched control was also 
included in Fig. 5.5. In contrast, 1 4 0 0 W (100 n M ) , an inducible N O S inhibitor, did not 
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modify vasodilatations induced by raloxifene in female arteries (P > 0.05, Fig. 5.6.). 
O n the contrary, 17p-estradiol-induced dilatation was unaffected by the treatment 
with 30 |iM L - N A M E (p/)2： 9.09 土 0.85 for control, 8.92 士 0.19 in L - N A M E , P > 0.05， 
Fig. 5.7.). 
5.4.3. Effect of CTX plus Apamin 
Co-treatment with C T X plus apamin, each at 50 n M , did not reduce both 
raloxifene-induced vasodilatation (P > 0.05, Fig. 5.8.). In contrast, 17p-estradiol-induced 
dilatation was attenuated by C T X plus apamin (P < 0.05, Fig. 5.9.). 
Raloxifene in concentrations of 0.3 or 1 n M did not modify the ACh-induced 
concentration-dependent vasodilatation in female rat arteries (Fig. 5.10a.). Dilatations to 
A C h were largely prevented by the exposure to C T X plus apamin, each at 50 n M (P < 
0.05，Fig. 5.10b. & c.). This suggests a major contribution of E D H F to ACh-induced 
vascular effect in rat resistance-sized mesenteric arteries. 
5.4.4. Effect of ICI 182,780 
ICI 182,780 at 1 )LIM did not reduce vasodilatation induced by raloxifene in female 
arteries with endothelium (pDi： 8.91 士 0.18 in control and 8.81 士 0.29 in ICI 182,780, ? > 
0.05, Fig.5.11.). Similarly, 17p-estradiol-induced dilatation in female arteries was 
unaltered by 1 ^ iM ICI 182,780 {P > 0.05，Fig. 5.12.). 
5.4.5. Effects of Wortmannin, LY 294002 and Cycloheximide 
- After a stable myogenic constriction was obtained, the incubation with wortmannin 
(50 n M , Fig.5.13a.), LY294002 (1 Fig.5.13b.) or cycloheximide (10 |aM, Fig.5.13c.) 
did not influence raloxifene-induced vasodilatations in female arteries with endothelium. 
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Fig. 5.1. Representative traces for raloxifene-induced dilatation in a 
mesenteric arterial ring with endothelium with snapshots during experiment in 
female (a) and in male (b). Development of myogenic tone took 
approximately 30 min to complete. Raloxifene was added cumulatively after 
every 30 min and a Ca^^-free Krebs containing 2 m M E G T A was added at the 
end,to obtain maximal passive vasodilatation. Scale bars apply to both 
’ traces. 
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Fig. 5.2. Concentration-response curve for raloxifene-induced dilatation in 
arteries with endothelium from female (〇）and male (•) rats. Data are 
expressed in percentage of dilatation. Statistical difference between curves is 
indicated (*** P < 0.001, two-way A N O V A ) . Data are mean 土 S.E.M. of 9 rats. 
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Fig. 5.3. Representative traces for estrogen-induced dilatation in female (a) 
and male (b) rings with endothelium. Scale bars apply to both traces, (c) 
Concentration-response curve for estrogen-induced dilatation in arteries with 
endothelium from female (〇）and male (•) rats. Statistical difference 
between curves is indicated (** P < 0.01, * P < 0.05, two-way A N OVA). Data 
are mean 土 S.E.M. of 5 rats. 
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Fig. 5.4. Representative traces for (a) raloxifene, (b) L - N A M E (30 ^iM), and 
“(c) time-matched control in female arteries with endothelium. To examine 
the effect of an e N O S inhibitor in arteries under myogenic tone, rings were 
exposed to 30 ]xM L-NAME for 30 min before cumulative addition of 
raloxifene. Scale bars apply to all traces. 
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Fig. 5.5. Concentration-response curve for raloxifene-induced dilatation in 
the absence (〇）and presence (•) of L - N A M E (30 |aM), and time-matched 
control (•) in female arteries with endothelium. Data are expressed in 
percentage of dilatation. Statistical difference between curves is indicated 
(** P < 0.01, two-way ANOVA). Data are mean 土 S.E.M. of 5-9 rats. 
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Fig. 5.6. Lack of the effect of 1400W (100 nM) (an iNOS inhibitor) (•) on 
raloxifene-induced dilatation (〇）in female arteries with endothelium. Data 
are expressed in percentage of dilatation. Data are mean 土 S.E.M. of 4-9 rats. 
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Fig. 5.7. (a) Representative trace for the effect of L - N A M E on estrogen-
induced dilatation 
in female rings with endothelium. Rings were exposed to 
30 jiM L - N A M E for 30 min before cumulative addition of 17p-estradiol. (b) 
Concentration-response curve (CRC) for the effects of L - N A M E (30 j^M) (•), 
17p-estradiol control (〇）and time-matched control (•) in female arteries with 
endothelium. Data are mean 土 S.E.M. of 5 rats. 
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Fig. 5.8. Concentration-response curve for raloxifene-induced dilatation in 
the absence (〇）and presence (•) of C T X + apamin (50 n M each) in female 
arteries with endothelium. Data are expressed in percentage of dilatation. 
Data are mean 土 S.E.M. of 8 rats. 
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Fig. 5.9. Concentration-response curve estrogen-induced dilatation in the 
absence (〇）and presence (•) of C T X + apamin (50 n M each) in female 
arteries with endothelium. Data are expressed in percentage of dilatation. 
Statistical difference between curves is indicated (* P < 0.05, two-way 
A N OVA). Data are mean 土 S.E.M. of 5 rats. 
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Fig. 5.10. (a) Concentration-relaxation curves for acetylcholine (ACh)-induced 
relaxation in myogenically-constricted rings with endothelium from female rats. 
“Rings were pretreated with raloxifene of 0.3 n M (•) or 1 n M (•) for 30 min 
before cumulative addition of ACh. Data are mean 土 S E M of 9 rats for control 
and 5 rats for 0.3 and 1 n M raloxifene, respectively, (b) Bar charts showing 
the modulation of A C h (500 nM)-induced dilating effect by C T X plus apamin 
(50 n M each) in female arteries with endothelium pretreated with 0.3 or 1 n M 
raloxifene. 
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Fig. 5.11. Concentration-response curve for raloxifene-induced dilatation in 
the absence (〇）and presence (•) of ICI 182,780 (1 ^ iM) in female arteries 
with endothelium. Data are expressed in percentage of dilatation. Data are 
mean 土 S.E.M. of 6-9 experiments. 
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Fig. 5.12. Concentration-response curve for raloxifene-induced dilatation in 
the absence (〇）and presence (•) of ICI 182,780 (1 ^ iM) in female arteries 
with endothelium. Data are expressed in percentage of dilatation. Data are 
mean 土 S.E.M. of 5 rats. 
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Fig. 5.13. The lack of dilatation-inhibitory effect of (a) wortmannin (50 nM), (b) 
LY294002 (1 |aM), and (c) cycloheximide (10 |iM) on raloxifene-induced 
dilatation in female arteries with endothelium. Statistical difference between 
the curves in (C) is indicated (* P < 0.05, two-way A N OVA). Data are 
expressed in percentage of dilatation. Data are mean 土 S.E.M. of 4-9 rats. 
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Fig. 5.14. Representative traces for the dilating effect of (a) raloxifene, (b) 
estrogen, and (c) time-matched control in male arteries with endothelium. 
Cumulative concentrations of raloxifene or 17p-estradiol (0.3-30 nM) were 
added into myogenically-constricted arteries. Scale bars apply to all traces. 
I 
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Fig., 5.15. Concentration-response curve for dilatation induced by raloxifene 
(〇)’ 17p-estradiol (•) and time-matched control (•) in male arteries with 
endothelium. Data are expressed in percentage of dilatation. Statistical 
difference between curves is indicated (** P < 0.01, two-way A N O V A ) . 
Data are mean 土 S.E.M. of 9’ 5 and 3 rats respectively. 
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5.5. Discussion 
The novel findings of the present investigation using pressurized rat resistance 
mesenteric arteries include: (1) therapeutic concentration of raloxifene reduced myogenic 
constriction in a concentration-dependent manner in rings with endothelium; (2) there 
was a gender difference in dilator responses to raloxifene with being more effective in 
female arteries; (3) endothelium-derived N O played a significant role in the 
raloxifene-induced vasodilatation; (4) dilatation to raloxifene was non-genomic and 
unrelated to ICI 182,780-sensitive estrogen receptor; (5) raloxifene did not modulate 
apamin plus CTX-sensitive dilatation to A C h ; (6) raloxifene-induced dilatation was 
unaffected by inhibitors of PI3K or inducible N O S ; and (7) 17p-estradiol also induced 
ICI 182,780-insensitive vasodilatation, which was inhibited by C T X plus apamin, but not 
by L - N A M E . It appears that 17p-estradiol was more effective at lower concentrations 
than raloxifene in causing vasodilatation and that there was similar gender difference in 
the vascular response to 17p-estradiol as observed in raloxifene-mediated vascular effects. 
The present study has thus provided the first piece of experimental evidence showing a 
potent vasodilating effect of raloxifene in female resistance arteries. 
According to the theory of Poiseuille, vascular resistance is directly proportional to 
the viscosity of the blood and the length of the vessels, and is inversely proportional to the 
radius of the vessels raised to the 4【卜 power [Resistance oc (viscosity x lengthyradW]. 
Under normal conditions, the radius is the most important factor in determining vascular 
resistance. Therefore, small resistance arteries primarily control the total peripheral 
resistance to blood flow. If the vasomotor activity in resistance arteries can be favorably 
modulated by S E R M s at therapeutic concentrations, the increased blood pressure in 
post-menopausal w o m e n with hypertension could be managed or even restored to normal 
levels. If this effect occurs in vivo, raloxifene is not only currently used in the prevention 
'and treatment of postmenopausal osteoporosis, but also useful against hypertension 
associated with menopause. 
Long-term oral administration of 60 mg/day of raloxifene hydrochloride in w o m e n 
is expected to result in a m e a n m a x i m u m plasma concentration of 1.36 |ig/L (Snyder et al. 
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2000; Morello et al, 2003) equivalent to 2.67 nmol/L of raloxifene. The present results 
clearly demonstrate that low concentrations of raloxifene caused potent vasodilating 
effect in resistance arteries, thus highlighting an very important mechanism by which 
raloxifene benefits the vascular system if this effect can be extended to in vivo conditions. 
Most published studies examined the effect of S E R M s or estrogen in mammalian blood 
vessels mounted for measurement of changes in isometric tension and m u c h higher 
concentrations of raloxifene were needed to induce vasorelaxation (Tsang et al., 2004a, 
b&c). However, it is unlikely that this high concentration of raloxifene can be achieved 
after normal dosing. A s above-mentioned, the maximal plasma concentration is around 3 
n M if patients are taking an oral dose of 60 m g daily (Snyder et al” 2000; Morello et al., 
2003). Thus the present study provides the first evidence demonstrating a potent 
vasodilator response to raloxifene in female resistance arteries in vitro. 
The present study examined the possible mechanisms involved in vasodilatations to 
both raloxifene and estrogen. It appears that raloxifene-induced dilatation is probably 
mediated, in larger part, through endothelium-derived N O since L - N A M E , a commonly 
used N O S inhibitor, significantly reduced the dilatations in rings with myogenic tone. In 
contrast, 1 4 0 0 W , the inducible N O S inhibitor was without effect. However, attempts were 
m a d e to examine the dependency on the endothelium of raloxifene-induced vascular 
effect but failed. Several techniques including mechanical denudation of endothelium or 
passing air through the lumen of arteries resulted in the loss of myogenic constriction. 
Without myogenic constriction, rings can be still constricted to the addition of 
phenylephrine, suggesting that the ring segment was not damaged by endothelium 
removing procedures. 
In contrast, raloxifene-induced dilatation was unchanged by treatment with C T X 
plus apamin, a recipe has been widely used to block K+-dependent EDHF-mediated 
response in small blood vessels (Edwards et al, 1998). C T X blocks inter-mediate - -
conductance Ca^^-activated K+ channels and apamin blocks small-conductance 
Ca^^-activated K + channels on endothelial cells (Busse et al., 2002). Acetylcholine 
caused vasodilatation which was largely inhibited by C T X plus apamin, suggesting a 
main role of E D H F , which is consistent with previous reports using the same or other 
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small arteries (Nakashima et al., 1997; Sendao et al, 2004). The present study also 
shows that treatment with raloxifene (0.3 and 1 n M ) did not modify ACh-induced 
NO-independent dilatation. 
The lack of effects of LY294002 (a selective PI3K inhibitor) and wortmannin (an 
irreversible PI3K inhibitor) suggest that PI3K pathway m a y not participate in the 
raloxifene-induced dilatation even though raloxifene was shown before to stimulate the 
production of N O in endothelial cells via estrogen-receptor-associated PI3K pathway in 
culture endothelial cells (Ogita et al., 2004; Simoncini et aL, 2002). It appears that the 
mechanisms responsible for the stimulatory effect of raloxifene on endothelial N O 
production and release m a y not be the same in freshly isolated small arteries and cultured 
endothelial cells since the experimental protocols are apparently very different, which 
m a y cause phenotypic changes in the endothelium in the case of cell culture. 
IVP-Estradiol was k n o w n to cause vasorelaxation via different mechanisms 
depending on the type of blood vessels used. For example, estrogen induced endothelium 
(NO)-dependent relaxation in rat aortas but endothelium-independent relaxation in large 
rat mesenteric arteries (Chan et al” 2001). This study shows that like raloxifene, estrogen 
also produced concentration-dependent dilatation and its effect appears to be more 
effective than raloxifene in female arteries. In contrast to raloxifene, estrogen-induced 
dilatation was unaffected by L - N A M E which inhibited a large portion of dilatation 
induced by raloxifene and the effect of estrogen was instead inhibited by treatment with 
C T X plus apamin. Taken together, the results indicate that different mechanisms account 
‘ for the dilatation induced by raloxifene and estrogen. The former is mediated by 
L-NAME-sensitive pathway while the latter is mediated by CTX/apamin-sensitive 
pathway. 
Gender difference was observed in both raloxifene- and 17p-estradiol-induced 
relaxation. Both raloxifene and 17p-estradiol led to greater extent of vessel dilatation in 
female than in male. Since both of them bind to ERs, this m a y be attributed to the fact 
that E R expression m a y be more profound in female mesenteric arteries than in the male 
counterparts. This is supported by various reports on the expression of ERs. O n e of the 
I 
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reports by Sharma and Thakur (2005) showed that the expression of E R a and E R p 
protein is differentially influenced by age, sex and gonadal steroids in A K R mouse 
cerebral cortex, suggesting differences in ER-mediated brain functions. Sharma and 
Thakur (2004) also revealed that the expression of E R a in mice kidney shows sex 
differences during aging. Therefore, E R expression m a y account for the gender 
discrepancy in relaxation induced by raloxifene and estrogen. 
Nongenomic effects of raloxifene m a y be mediated through activation of ERs. The 
selective estrogen receptor antagonist ICI 182,780 did not antagonize raloxifene-induced 
relaxation, indicating that ICI 182,780-sensitive E R s were not involved in 
raloxifene-induced dilatation. Similarly, the lack of effect of ICI 182,780 on 
estrogen-induced relaxation means that ICI 182,780-sensitive E R s did not take part in the 
vasorelaxation. However, it is still unclear h o w raloxifene m a y act on Ca^"^ channels in 
vascular smooth muscle if its effect is not mediated by ERs. Estrogen was shown to 
activate Ca^^-actiavted K + channels by a direct interaction with the (3-subunit of the 
channel protein (Valverde et al, 1999). It still has to be elucidated whether the Ca^^ 
channel could provide such an interactive site for raloxifene. The lack of effect of 
raloxifene (0.3 and 1 n M ) on ACh-induced relaxation, which can be reversed by apamin 




In conclusion, the present findings reveal that raloxifene, a T ^ generation S E R M 
used to treat and prevent osteoporosis, at therapeutic doses (0.3-30 n M ) could dilate rat 
pressurized small resistance mesenteric arteries via an endothelium/NO-dependent 
mechanism. This action is non-genomic and independent of ICI 182,780-sensitive ERs, 
iNOs and PI3K. The present in vitro data show that raloxifene is more effective in 
causing mesenteric vascular relaxation in female than male animals. However, it remains 
to be examined whether raloxifene could exert similar gender-related effects in vivo for 
the small resistance mesenteric arteries with myogenic tone. B y enhancing resistance 
artery sensitivity to agonists (Dunn et al., 1994), isobaric condition provides more 
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important and convincing data than the isometric model. Raloxifene, being found to be 
effective in causing vasodilatation at therapeutic doses, m a y be also a promising agent to 
treat or prevent hypertension besides osteoporosis. 
• I 
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CHAPTER VI 
Effects of Chronic Raloxifene Treatment on 
Vascular Reactivity in Pressurized Septal 
Coronary Arteries from Hamsters Fed with 
High-Cholesterol Diet 
6.1. Abstract 
Although selective estrogen receptor modulators ( S E R M s ) have already been 
developed for some years, whether S E R M s could modulate myogenic tone in resistance 
vessels is not studied. The impact of high-cholesterol ( H C ) diet, ovariectomy and 
raloxifene therapy on myogenic tone is unknown. The present study aimed to investigate 
the changes in vascular reactivity and myogenic responses in septal coronary arteries 
from female hamsters fed with H C diet with and without ovariectomy ( O V X ) and/or 
chronic treatment of raloxifene. The effects on myogenic tone and vasoreactivity were 
examined in isolated arteries cannulated on a pressure myograph chamber. 
In summary, this was the first study showing (1) that O V X tended to reduce 
ACh-induced vasodilatation in arteries with endothelium from control hamsters without 
affecting pressure-induced myogenic constriction; (2) chronic raloxifene treatment 
enhanced ACh-induced vasodilatation in ovariectomized hamsters; (3) O V X enhanced 
“ U46619-induced vasoconstriction after the development of myogenic tone in arteries 
with endothelium and raloxifene treatment normalized this effect in ovariectomized 
hamsters; and (4) myogenic tone was not affected by 30-min treatment with L - N A M E (30 
I^M). The present results show that raloxifene could benefit coronary arteries by reducing 
agonist-induced vascular constriction without affecting myogenic responses in 
high-cholesterol diet fed ovariectomized old hamsters. 
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6.2. Introduction 
Myogenic response (or myogenic tone), first described by Bayliss in 1902 (Bayliss, 
1902), refers to a spontaneous decrease or increase in vessel diameter after raising or 
reducing transmural pressure respectively. This response provides a basal tone for 
arterioles to adjust diameters in response to neurohumoral stimuli, controlling basal 
peripheral vascular resistance and capillary hydrostatic pressure (Johnson, 1981; Davis et 
al, 1999). This ensures a constant blood flow over a wide range of pressures, especially 
in the brain, heart and kidneys (Johnson, 1989; Muller et al., 1996; Faraci et al., 1989; 
R o m a n and Harder, 1993). Estrogen was found to reduce myogenic response by 
elevating basal N O release from endothelial cells of rat coronary arteries, causing 
increases in vessel diameters (Wellman et al, 1996). Raloxifene, at therapeutic 
concentrations, also relaxes rat small resistance mesenteric arteries (see Chapter 5). 
Diet with high levels of fat and cholesterol is normally used to increase the total and 
low-density lipoprotein cholesterol (LDL-C) in animal models such as hamsters and 
rabbits. In general, high levels of plasma L D L - C are associated with increased risks of 
cardiovascular diseases, such as coronary heart disease (CHD), myocardial infarction, 
and stroke (Lockman et al, 2005). In w o m e n with documented C H D in M O R E study 
(Ettinger et al, 1999), raloxifene reduced total and L D L - C (Harper et al, 2000). A n 
average decrease in total cholesterol level and L D L - C of around 8 and 12 % was reported, 
respectively, after raloxifene therapy in w o m e n (Barrett-Connor et al, 2002). 
I� 
Though estrogen has been shown to reduce myogenic response, it is u n k n o w n 
whether raloxifene could modulate myogenic tone. The purpose of the present study was 
to examine the changes in vascular reactivity and myogenic responses in septal coronary 
arteries from female hamsters fed with H C diet with and without ovariectomy ( O V X ) 
.and/or chronic treatment of raloxifene. 
t 
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6.3. Methods and Materials 
6.3.1. Preparatory Work 
6.3.1.1. Animals and Diets 
This study was approved by the Animal Research Ethics Committee of Chinese 
University of H o n g Kong. This investigation conformed to the Guide for the Care and 
Use of Laboratory Animals published by the U S National Institute of Health (NIH 
Publication No.85-23，revised 1996). There were 22 old female Syrian golden hamsters 
(〜12-month old, weighing 〜120 - 200 g) randomly divided into four groups: O H H C D 
(old hamster fed high cholesterol diet), O H H C D R f (old hamster fed high cholesterol diet 
receiving raloxifene), O v x O H H C D (ovariectomized old hamster fed high cholesterol diet) 
and O v x O H H C D R f (ovariectomized old hamster fed high cholesterol diet receiving 
raloxifene). O H H C D R f and O v x O H H C D R f were subjected to raloxifene therapy, while 
O v x O H H C D and O v x O H H C D R f underwent ovariectomy ( O V X ) . They were all given 
free access to high-cholesterol ( H C ) diet and drinking water and maintained under a 
controlled condition of humidity (47 — 48 % ) , temperature (20。C) and light (12 hours of 
light, 12 hours of dark). 
6.3.1.2. Preparation of High-Cholesterol (HC) Food 
H C diet was prepared by using different proportions of the following ingredients: 
casein, lard, starch, sucrose, mineral mix, vitamin mix, DL-methionine, pure cholesterol, 
»‘ 
dietary, fibre, and gelatin. The diet contains 0.1 % pure cholesterol and a 4-fold of lard 
than normal diet (Table 2.6c. in section 2.6.3. of Chapter 2). Gelatin solution (20 g/L), in 
a ratio of 1 kg diet per litre of solution, was used to mix all the powdered diets. Once the 
gelatin had set, the diet was cut into approximately 10 g cubic portions and stored at — 20 
6.3.1.3. Surgical Procedure - Ovariectomy (OVX) 
Old female Syrian golden hamsters 12-month old, weighed about 120 - 200 g) 
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were supplied by the Laboratory Animal Services Center, the Chinese University of H o n g 
K o n g . They were divided into four groups as mentioned in section 6.3.1.1. O v x O H H C D 
and O v x O H H C D R f groups were anaesthetized with 3 m l of a mix of ketamine and 
xylaxine (1.5 to 1，v/v) per kg body weight. Bilateral O V X was done aseptically via a 
mid-abdominal route. T w o weeks after O V X , the ovariectomized hamsters were 
randomly divided into two groups ( O V X and O V X + raloxifene) and allowed free access 
to H C diet and drinking water. 
6.3.1.4. Surgical Procedure 一 Raloxifene-filled Tubing Insertion 
T w o weeks after O V X , O v x O H H C D and O v x O H H C D R f groups were anaesthetized 
with 3 m l of a m i x of ketamine and xylaxine (1.5 to 1, v/v) per kg body weight to insert 
subcutaneously with a raloxifene powder-filled Silastic® tubing ( D o w C o m i n g ) in the 
back. After insertion, they were placed in separate cages and given free access to H C 
food and drinking water for three months. All hamsters were maintained under a 
controlled condition of humidity (47 - 48 % ) , temperature (20。C) and light (12 hours of 
light, 12 hours of dark) before sacrifice. 
6.3.1.5. Blood Vessel Preparation 
A hamster was euthanized by C O 2 inhalation at the time of sacrifice. The heart was 
carefully dissected out and placed in ice-cold Krebs solution. Septal coronary arteries 
(outer diameter:〜250 fim) were dissected free from hearts and the surrounding 
tt 
connective tissue was cleaned off under a dissecting microscope. Each blood vessel was 
cut into a 2 - 3 m m long ring segment. Each ring segment was mounted on a Pressure 
Myograph System (Danish M y o Technology, Denmark) and changes in vessel diameter 
were measured. 
Briefly, the ring segment was cannulated between the two glass cannulas, each with 
diameter of 〜100 |im, in a 10-ml chamber filled with Krebs solution. The chamber 
solution was continuously bubbled with 9 5 % 0 2 - 5 % C O 2 and maintained at 37 (pH 
7.4), monitored by a temperature probe. O n e end of a ring segment was first secured on a 
( 
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cannula with two fine nylon sutures (Danish M y o Technology, Denmark), it was then 
flushed with Krebs solution at pressure difference less than 20 m m H g to clear any 
intraluminal blood in the lumen. Another end of the segment was thereafter cannulated. 
Glass cannulas were pulled with a micropipette puller model P-87 (Shutter Instrument 
Company, Novato, CA). Both cannulating pipettes were connected to independent 
Krebs-containing buffer bottles seated on a pressure regulator. The regulator controlled 
the flow rate and pressure applied to the segment mounted on the pressure myograph 
chamber. Under no-flow condition, myogenic tone was allowed to fully develop before 
an experimental maneuver. A video camera attached to a light-inverted microscope 
(Zeiss Axiovert 40 Microscope, Model H O P ) was used to visualize the segment of an 
artery, and data were recorded to disk. Outer diameters of the vessels and luminal 
pressure were measured continuously using the software M y o - V i e w (version 1.1 P, 2000, 
Photonics Engineering, Denmark). 
6.3.1.6. Body Weight, Food Consumption and Uterine Weight 
B o d y weights of hamsters were measured once a week. Food consumption was 
measured twice a week. Wet weights of uteri were measured at the time of sacrifice (Fig. 
6.17.). 
6.3.1.7. Measurement of Raloxifene Tubing Consumption 
Before insertion, the initial weight of the raloxifene-filled tubing was measured. At 
“ the time of sacrifice, the inserted tubing was removed, dried overnight with an oven, and 
then weighed again. 
B y subtracting the final weight of the tubing from the initial value, the amount of 
raloxifene released in grams was obtained. The average amount of raloxifene released in 
a kg body weight of a hamster per day was 0.0986 )ig/kg/day. 
CHAPTER VI _ RALOXIFENE EFFECT IN PRESSURIZED SEPTAL CORONARY ARTERY/ 1 3 2 
6.3.1.8. Serum Lipid and Lipoprotein Determinations 
Serum triglycerides (TG) and total cholesterol (TC) levels were determined by 
using enzymatic kits (Sigma Chemical, St. Louis, M O , U S A ) . High-density lipoprotein 
cholesterol ( H D L - C ) was measured after precipitation of low-density lipoprotein ( L D L ) 
and very low-density lipoprotein ( V L D L ) with phosphotungstic acid and magnesium 
chloride, using a commercial kit (Sigma). 
6.3.2. Experimental Protocols 
6.3.2.1. Development of Myogenic Tone 
After a vessel was mounted, intraluminal pressure was gradually increased from 20 
to 100 m m H g in room temperature and 5 min was given for each pressure increment. 
After this procedure, the intraluminal pressure was returned to and maintained at 80 
m m H g . The temperature of the superfusion was warmed up gradually from room 
temperature to 37 °C by switching on a pre-installed heating device in the pressure 
myograph chamber. The chamber solution was kept at 37 °C during the remaining 
duration of the experiments and monitored by a built-in temperature probe. The heating 
procedure took around 30 min. W h e n the superfusate temperature reached at 37 the 
myogenic tone develops sharply, causing a sudden decrease in vessel diameter. The 
vessel diameter normally stabilized after 10-20 min, suggesting a successful development 
of myogenic constriction. 
“ 6.3.2.2. Pressure-Diameter Relationships 
To compare differences in amplitude of myogenic tone developed in different 
treatment groups of hamsters, The pressure-diameter relationship was obtained by 
increasing the intraluminal pressure from 20 to 120 m m H g in 20 m m H g increment in 
- • 
each myogenically active septal coronary artery at 37 °C and five min was allowed for the 
vessel to achieve a steady-state diameter at each n e w pressure. Changes in outer vessel 
diameter at each intramural pressure were recorded. At the end of each experiment, the 
vessel was exposed to a Ca^'^-free superfusate containing 2 m M E G T A and another 
I 
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pressure-diameter curve was repeated in order to obtain a maximal passive vasodilatation 
at each pressure for the purpose of data analysis. 
6.3.2.3. The Effect of Acetylcholine 
To examine the effects of A C h after development of myogenic tone, A C h (3 n M - 3 0 
|j,M) was added cumulatively to the superfusate to induce concentration-dependent 
dilatation. The intraluminal pressure of the cannulated artery was maintained at 80 
m m H g and changes in outer diameters of vessels were recorded throughout the entire 
duration of the experiment. 
6.3.2.4. The Effect of U46619 
After a stable myogenic constriction was obtained, U46619 (1 n M - 300 n M ) was 
added cumulatively to the superfusate to induce further constriction. The intraluminal 
pressure was maintained at 80 m m H g and changes in outer vessel diameters were 
recorded during the entire duration of the experiment. 
6.3.2.5. The Effect of L-NAME 
To examine whether endothelial N O was involved in changes in either myogenic 
tone before and after chronic raloxifene treatment, the myogenic constriction was 
recorded in the absence and presence of 30 fiM L - N A M E , a N O S inhibitor, in 
•‘ myogenically-constricted arteries from different treatment groups. L - N A M E was added 
to the superfusate after a complete development of myogenic tone. After 30-min 
incubation, each artery was subjected to intraluminal pressure step increments (20 to 120 
m m H g ) . Changes in outer vessel diameters were recorded. 
6.3.3. Drugs and Solutions 
17P-estradiol, Acetylcholine [2-(acetyloxy)-7V,iV’A^-trimethylethanaminium], 
L - N A M E , and U46619 [9,11 -Dideoxy-11 a,9a-epoxymethano-prostaglandin F2a] were 
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purchased from Sigma. Ethyleneglycotetraacetic acid ( E G T A ) was bought from 
Invitrogen Corporation, while Raloxifene 
[[6-hydroxy-2-(4-hydroxyphenyl)benzo[^]thiophen-3-yl][4-[2-piperidinoethoxy]phenyl 
]ketone hydrochloride] was a gift from Lilly Corporate Center (Indianapolis, IN, U S A ) . 
Raloxifene and U46619 were dissolved in D M S O (Sigma) and others in distilled 
water. Further dilution was made from stock solutions. Krebs solution contained (in 
m M ) : 119 NaCl, 4.7 KCl, 2.5 C a C b , 1 M g C b , 25 N a H C O j , 1.2 KH2PO4, and 11 D-glucose 
(section 5.6.2., table 2.6b.). Ca^^-free Krebs solution was identical to Krebs solution with 
the exclusion of Ca^^ and the addition of 2 m M E G T A . 
6.3.4. Expression of Results and Statistical Analysis 
The pressure-diameter relationship and the effect of L - N A M E were presented as 
normalized diameter versus intraluminal pressure curves. Normalized diameter ( N D ) = 
active diameter / maximal passive diameter. Active diameter was vessel diameter under 
myogenic tone at a particular pressure and maximal passive diameter was diameter 
measured in the absence of Ca^^ at a particular pressure. N D was adopted instead of the 
absolute values of vessel diameter to eliminate any difference in diameters of various 
vessels. 
The effects of A C h and U46619 were expressed as percentages of myogenic tone ( % 
M T ) at 80 m m H g versus concentration of A C h or U46619. % M T = 
” (Dniax-Dp)/(Dmax-D8o) X 100%, where Dmax = maximal passive diameter in the absence of 
Ca2+; D p = diameter at the particular concentration of A C h or U46619; D s o : stabilized 
active diameter after complete development of myogenic tone at 80 m m H g . 
All results are expressed as mean 士 S.E.M. of n animals. Each vessel subjected to 
experiment was isolated from a single animal. Two-way Analysis of variance ( A N O V A ) 
followed by Bonferroni post-tests was used for statistical evaluation w h e n more than two 
groups were compared. P < 0.05 was taken to be statistically significant between two 
groups. 
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6.4. Results 
The myogenic response and agonist-induced dilatation or constriction were studied 
in septal coronary arteries with endothelium in the following groups of hamsters: 
O H H C D and O v x O H H C D , O v x O H H C D and O v x O H H C D R f , O H H C D R f and 
O v x O H H C D R f , as well as O H H C D and O H H C D R f . 
6.4.1. Effects on Myogenic Response 
Pressure-induced myogenic constrictions in arteries with endothelium from all the 
four groups of hamsters were not altered in different paired groups (P > 0.05 in all cases, 
Fig. 6.1.，6.5.，6.9. & 6.13.). 
6.4.2. Effects of Acetylcholine, U46619 and L-NAME 
6.4.2.1. OHHCD and OvxOHHCD 
After the steady-state development of myogenic tone in the resistance arteries with 
endothelium, application of acetylcholine (ACh, 3 n M - 30 caused 
concentration-dependent dilatation and this dilatation was similar in arteries from 
O H H C D and O v x O H H C D (P > 0.05, Fig. 6.2.). U46619 (1 n M - 300 n M ) caused 
concentration-dependent vasoconstriction in arteries from O v x O H H C D as compared 
with those from O H H C D (P < 0.05, Fig. 6.3.). 
«» 
L - N A M E did not modify pressure-induced constriction in arteries from O H H C D 
and O v x O H H C D as shown in Fig. 6.4a. & b. The area between the two curves indicates 
degrees of the contribution of basal N O to pressure-induced myogenic constriction. Fig. 
6.4c. shows that there is no difference in the L-NAME-sensitive tone of arteries between 
. O H H C D and O v x O H H C D (P > 0.05). 
6.4.2.2. OvxOHHCD and OvxOHHCDRf 
The pressure-induced constriction was similar in rings from O v x O H H C D and 
I 
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O v x O H H C D R f (Fig. 6.5.). A C h (3 n M - 30 j^M) induced a biphasic vascular response in 
arteries with endothelium from O v x O H H C D : vasoconstriction at concentrations between 
3 n M and 3 jjJM A C h , while vasodilatation at concentration higher than 3 |iM. After 
raloxifene treatment in arteries from O v x O H H C D R f , A C h induced significantly more 
vasodilatation after the development of myogenic tone {P < 0.05, Fig. 6.6.). 
U46619 (1 - 300 n M ) induced vasoconstriction in arteries with endothelium from 
O v x O H H C D after the development of myogenic response (Fig. 6.7.). Raloxifene 
treatment suppressed the U46619-induced constriction in arteries from O v x O H H C D R f 
{P < 0.05, Fig. 6.7,). 
L - N A M E did not alter myogenic tone in arteries with endothelium from 
O v x O H H C D and O v x O H H C D R f (Fig. 6.8a.& b.). There was no difference between the 
L-NAME-sensitive tones in arteries from the two groups {P > 0.05, Fig. 6.8c.). 
6.4.2.3. OHHCDRf and OvxOHHCDRf 
The pressure-induced constriction was similar in rings from O H H C D R f and 
O v x O H H C D R f (Fig. 6.9.) and both groups of hamsters were chronically treated with 
raloxifene. 
A C h induced vasodilatation in arteries with endothelium from O H H C D R f and 
ovariectomy had no effect since dilatation was similar between O H H C D R f and 
•‘ O v x O H H C D R f CP > 0.05, Fig. 6.10.). U46619-induced vasoconstriction was similar in 
arteries from both groups (Fig. 6.11.). L - N A M E failed to modulate pressure-induced 
constriction in arteries from O H H C D R f and O v x O H H C D R f (Fig. 6.12a.& b.) since 
L-NAME-sensitive tone was basically the same between the two groups {P > 0.05, Fig. 
6.12c.). 
6.4.2.4. OHHCD and OHHCDRf 
Chronic raloxifene treatment did not modify pressure-induced vasoconstriction of 
I 
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arteries from O H H C D (Fig. 6.13.). 
After a stable myogenic tone was obtained, vasodilatation to A C h or 
vasoconstriction to U46619 was similar between O H H C D and O H H C D R f (Fig. 6.14. & 
Fig. 6.15.). L - N A M E did not affect pressure-induced constriction in arteries from the two 
groups of hamsters. (Fig. 6.16.) 
- • 
t 
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(mmHg) 
Fig. 6.1. Pressure-diameter curves are not different (expressed as normalized 
diameter) in myogenically active septal coronary arteries with endothelium 
from O H H C D (〇）and O v x O H H C D (•) groups. Data are mean 土 S.E.M. of 5-6 
. hamsters. 
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Fig. 6.2. Concentration-dependent effect of acetylcholine (ACh) 
[vasoconstriction at low concentrations (3 n M - 3 _ but vasodilatation at 
“ higher concentrations (> 3 |aM)] in arteries with endothelium from O H H C D (〇） 
and O v x O H H C D (•). Data are mean 土 S.E.M. of 5-6 hamsters. 
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Fig. 6.3. U46619 induced-effect on vessel diameter after the development of 
myogenic tone in arteries with endothelium from O H H C D (〇）and O v x O H H C D 
(•). Statistical difference between curves is indicated (** P < 0.01, two-way 
• A N OVA). Data are mean 土 S.E.M. of 5-6 hamsters. 
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Fig. 6.4. L - N A M E did not modify myogenic constrictions in arteries from (a) 
O v x O H H C D and (b) O H H C D . (c) L-NAME-sensitive tone is expressed as a 
difference in normalized diameters from O v x O H H C D (•) and O H H C D (〇）and 
no significant difference was found. Data are mean 土 S.E.M. of 5-6 hamsters. 
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(mmHg) 
Fig. 6.5. Pressure-diameter curves showing no difference (expressed as 
normalized diameter) in myogenically active arteries with endothelium from 
O v x O H H C D (〇）and O v x O H H C D R f (•). Data are mean 土 S.E.M. of 6 
hamsters. 
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Fig. 6.6. ACh-induced vasodilatation after the development of myogenic tone 
in arteries with endothelium between O v x O H H C D (〇）and O v x O H H C D R f (•). 
Statistical difference between curves is indicated (* P < 0.05，two-way 
A N O V A ) . Data are mean 土 S.E.M. of 6 hamsters. 
- . 
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Fig. 6.7. U46619-induced vasoconstriction after a stable development of 
myogenic tone in arteries with endothelium from O v x O H H C D (〇）and 
O v x O H H C D R f (參).Statistical difference between curves is indicated (** P < 
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Fig. 6.8. L - N A M E did not modify myogenic tone in endothelium-intact arteries 
from (a) O v x O H H C D and (b) O v x O H H C D R f . (c) No difference in 
‘L-NAME-sensitive tone expressed as a difference in normalized diameters 
between O v x O H H C D (〇）and O v x O H H C D R f (•). Data are m e a n 士 S.E.M. of 
6 and 5 hamsters. 
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Fig. 6.9. Pressure-diameter curves showing no change in normalized 
diameter in myogenically active septal coronary arteries with endothelium from 
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Fig. 6.10. ACh-induced vasodilatation in myogenic tone-developed arteries 
with endothelium from O H H C D R f (〇）and O v x O H H C D R f (•). Data are mean 
土 S.E.M. of 5-6 hamsters. 
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Fig. 6.11. U46619-induced constriction after the development of myogenic 
tone in arteries with endothelium from O H H C D R f (〇）and O v x O H H C D R f (參). 




CHAPTER VI 一 RALOXIFENE EFFECT IN PRESSURIZED SEPTAL CORONARY ARTERY/ 
(a) ^ 1.1. 
II： X . 
O Q 0.8- ^ ^ 
乙 ^ OHHCDRf Control 
0.7」"^L-NAME 
0 20 40 60 80 100 120 140 
(b) 
1 1-1 
" O -o- OvxOHHCDRf Control 
§ S 1.0- + L-NAME 
1： 
OjJ +Endo 
, 、 6 20 40 60 80 100 140 
(C) 
02-1 
" D ① OvxOHHCDRf 
^ (D O -o-OHHCDRf 
~ 0 § — 0.1- I 
•0.1」 +Endo 
6 20 40 60 80 100 120 140 
Intraluminal Pressure 
_ H g ) 
Fig. 6.12. L - N A M E did not modify myogenic tone in arteries with endothelium 
from (a) O H H C D R f and (b) O v x O H H C D R f . (c) No difference in 
L-NAME-sensitive tone expressed as a difference in normalized diameters 
’ between O H H C D R f (〇）and O v x O H H C D R f (參）.Data are mean 土 S.E.M. of 5 
hamsters. 
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Fig. 6.13. Pressure-diameter curves showing no difference in normalized 
diameter in myogenically active septal coronary arteries with endothelium from 
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Fig. 6.14. ACh-induced dilatation after the development of myogenic tone in 
arteries with endothelium from O H H C D (〇）and O H H C D R f (•). Data are 
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Fig. 6.15. U46619-induced vasoconstriction in myogenic tone developed 
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Fig. 6.16. L - N A M E did not modify myogenic tone in arteries from (a) O H H C D 
‘and (b) O H H C D R f . (c) No difference in L-NAME-sensitive tone expressed as a 
difference in normalized diameters between O H H C D (〇）and O H H C D R f (•). 
Data are m e a n 土 S.E.M. of 5 hamsters. 
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Fig. 6.17. Wet weights of uteri from the four groups of hamsters: O H H C D , 
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6.5. Discussion 
The novel findings of the present investigation using pressurized hamster septal 
coronary arteries from old female hamsters include: (1) ovariectomy ( O V X ) tended to 
reduce ACh-induced vasodilatation in arteries with endothelium from control hamsters 
without affecting pressure-induced myogenic constriction; (2) chronic raloxifene 
treatment enhanced ACh-induced vasodilatation in ovariectomized hamsters; (3) O V X 
enhanced U46619-induced vasoconstriction after a stable development of myogenic tone 
in arteries with endothelium and raloxifene treatment normalized this effect in 
ovariectomized hamsters; (4) myogenic tone was not affected by treatment with 
L - N A M E . The present study has thus provided the first piece of experimental evidence 
showing the chronic effect of raloxifene on coronary arteries which are routinely able to 
develop myogenic constriction by an L-NAME-insensitive mechanism in female 
hamsters fed with high-cholesterol diet. 
A m o n g the few published data, O V X has been shown to increase myogenic tone in 
coronary artery. Mericli et al. in 2004 reported an increased spontaneous myogenic tone 
of coronary arteries {P < 0.05) in female Sprague-Dawley (SD) rats after O V X . Another 
report in septal coronary arteries from S D rats (Wellman et al., 1996) indicated that 
myogenic tones were greater (approximately two-fold) in isolated coronary arteries from 
estrogen-deficient male or ovariectomized rats compared with those from female rats or 
O V X rats receiving estrogen replacement ( O V X + E 2 ) . Geary et al. in 1998 also showed a 
greater myogenic tone in middle cerebral arteries from male and O V X female as 
»I 
compared with arteries from either untreated or O V X + E2 females. Before the present 
study, there was no report regarding the effect of chronic raloxifene treatment on 
modulation of myogenic tone in septal coronary artery from old female hamsters with and 
without O V X . 
- • 
In the present study, in contrast to previous reports by Mericli et al. in 2004 and 
Wellman et al. in 1996 in rats, O V X did not modify myogenic responses in septal 
coronary arteries from female hamsters, suggesting a species difference in the role of 
circulating estrogen in the regulation of myogenic activity. ACh-induced vasodilatation 
I 
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tended to be reduced in arteries of ovariectomized hamsters. Chronic raloxifene treatment 
enhanced ACh-induced dilatation in ovariectomized hamsters. Besides, U46619-induced 
vasoconstriction was enhanced by O V X in arteries after a full development of myogenic 
tone. This effect in ovariectomized hamsters was normalized by raloxifene treatment, 
suggesting raloxifene could modulate agonist-induced constriction in ovariectomized 
hamsters. 
Since raloxifene is used mainly in the prevention and treatment of osteoporosis in 
postmenopausal w o m e n , it will be additional benefits to osteoporotic patients with 
cardiovascular diseases if chronic raloxifene therapy can improve diminished vascular 
function in these patients. The results of the present study suggest the vascular benefits of 
raloxifene in female hamsters following ovariectomy. 
6.6. Conclusion 
In summary, the present results reveal that chronic treatment with raloxifene, a 
2nd-generation S E R M clinically used to prevent and treat postmenopausal osteoporosis, 
increased ACh-induced vasodilatation and reduced the enhanced vasoconstriction to 
U 4 6 6 1 9 in myogenically active septal coronary arteries with endothelium in old 
ovariectomized female hamsters fed with high cholesterol diet, without involving 
L-NAME-sensitive pathway. The data indicate a beneficial effect of raloxifene on 
coronary vascular circulation by normalizing alterations in vascular reactivity during 
estrogen deficiency. If this effect of raloxifene can be extended to h u m a n coronary 
I� 
arteries, chronic raloxifene therapy m a y improve coronary blood flow and benefits 
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